Ericdao的个人主页 - 老虎社区

Ericdao

Ericdao

暂无个人介绍

IP属地：未知

389关注

14粉丝

0主题

0勋章

2021-09-10

See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped

抱歉，原内容已删除

2021-09-05

This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt

抱歉，原内容已删除

2021-10-15

Too high already, time for it to cool down

抱歉，原内容已删除

2021-11-26

Will it ? Well market is insane, anything can happen [开心] [开心]

抱歉，原内容已删除

2021-10-04

Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful

3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote>

2021-10-04

V good recommendations. I will include visa also

抱歉，原内容已删除

2021-12-18

Semicon industry nvr die

Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>

2021-08-12

Not worth buying. Follow her and die faster

抱歉，原内容已删除

2021-10-17

GOOD PICK

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574662162410712","uuid":"3574662162410712","gmtCreate":1611568139053,"gmtModify":1628390403937,"name":"Ericdao","pinyin":"ericdao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":14,"headSize":389,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.07.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.39%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":630619131,"gmtCreate":1642812029157,"gmtModify":1642812029359,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Cathy will be gone soon&nbsp;","listText":"Cathy will be gone soon&nbsp;","text":"Cathy will be gone soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/630619131","repostId":"1116834406","repostType":4,"isVote":1,"tweetType":1,"viewCount":3852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":697840047,"gmtCreate":1642415216001,"gmtModify":1642415216206,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/697840047","repostId":"1131862461","repostType":4,"repost":{"id":"1131862461","kind":"news","pubTimestamp":1642412568,"share":"https://www.laohunote.com/m/news/1131862461?lang=zh_CN&edition=full","pubTime":"2022-01-17 17:42","market":"us","language":"en","title":"Moderna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格下的高上涨潜力</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1131862461","media":"Seeking Alpha","summary":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-","content":"<p><html><head></head><body><b>Summary</b></p><p><blockquote><html><head></head><body><b>总结</b></body></html></blockquote></p><p><ul><li>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity.</li><li>Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.</li><li>Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.</li><li>One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.</li><li>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/466434ab0d3291095a83741482c15948\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"/><span>Maddie Meyer/Getty Images News</span></p><p><blockquote><ul><li>Moderna 不仅通过开发 COVID-19 疫苗，而且通过扩大公司的 mRNA 制造能力，拥有显着的先发竞争优势。</li><li>Moderna 最近报告称，COVID-19 对 2021 年产品销售额的初步估计约为 175 亿美元。</li><li>最近，新加坡公布的数据显示，新冠肺炎死亡率是Moderna疫苗接种者中最低的。</li><li>Moderna 在潜在 mRNA 竞争中保持领先地位的方法之一是利用其 153 亿美元现金和 32 亿美元自由现金流继续在全球范围内建立强大的 mRNA 制造能力。</li><li>Moderna 的历史高点 497.49 美元回调 58%，让激进的成长型投资者有机会买入一家具有巨大上涨潜力的公司。</li></ul><p class=\"t-img-caption\"><span>麦迪·迈耶/盖蒂图片社新闻</span></p></blockquote></p><p>Moderna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world&#39;s most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.</p><p><blockquote>Moderna（纳斯达克股票代码：mRNA）作为开发世界上最先进的mRNA平台的先行者，具有极高的上涨空间。帮助预防或治愈人类已知的一些最棘手疾病的最有前途的潜在解决方案之一是mRNA技术，Moderna不仅开发了最先进的mRNA平台，还在全球范围内建立了强大的mRNA制造能力。有许多公司处于开发mRNA技术的不同阶段，但很少有公司像Moderna一样在开发mRNA技术以及拥有每年生产数十亿剂疫苗的制造能力和其他商业基础设施方面取得如此进展。目前，唯一拥有先进 mRNA 技术知识和制造能力与 Moderna 在同一舞台上竞争的公司是 BioNTech（纳斯达克股票代码：BNTX）-辉瑞（纽约证券交易所股票代码：PFE）合作伙伴关系。</blockquote></p><p>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna&#39;s first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.</p><p><blockquote>Moderna 不仅通过开发 COVID-19 疫苗，而且通过扩大公司的 mRNA 制造能力，拥有显着的先发竞争优势。在实验室环境中生产mRNA是一回事，但在世界各地监管机构批准的生产基地安全地大规模生产有效疫苗则是另一回事。Moderna 的先发优势已转化为来自 COVID-19 销售的巨额现金，该公司可以通过投资推进 mRNA 技术、改进 mRNA 制造工艺以及在全球范围内建立强大的制造能力来进一步扩大其领先地位。Moderna 还在开发世界上最深的药物管道之一方面进展顺利。</blockquote></p><p>While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna&#39;s mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna&#39;s stock today.</p><p><blockquote>虽然先发优势并不完全是护城河，但至少在未来几年内，Moderna 应该在开发许多不同的基于 mRNA 的疗法或疫苗来治疗许多难以治疗的疾病方面享有显着的领先地位。Moderna 目前拥有 40 个不同的药物开发项目，这对于一家相对年轻的生物技术公司来说几乎是闻所未闻的，两年前它还只是一个研究机构。最终，Moderna 的 mRNA 平台和制造能力应该会为今天购买 Moderna 股票的投资者带来显着的长期上涨空间。</blockquote></p><p>Advantages of mRNA Technology</p><p><blockquote>mRNA技术的优势</blockquote></p><p>The reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.</p><p><blockquote>Moderna之所以能够快速开发出新冠肺炎解决方案，同时继续构建大量药物开发项目，是因为mRNA技术的本质。</blockquote></p><p>The development and manufacturing of mRNA for use as therapeutics<i>and</i>vaccines are comparatively simple, scalable<i>and</i>extremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people&#39;s arms. Eventually, this response time could shrink to matter of a few months.</p><p><blockquote>用作治疗剂的mRNA的开发和制造<i>和</i>疫苗相对简单，可扩展<i>和</i>极快。资料来源：Millapore Sigma mRNA 平台与传统药物制造相比具有许多优势。对新冠肺炎疫情的反应证明了mRNA平台的主要优势，即能够获取病毒序列，并在非常短的时间内快速从开发、临床试验、批准到疫苗的大规模生产。随着 Moderna 和其他公司获得更多经验，监管机构对 mRNA 技术更加满意，我可以预见未来有一天，发现毒性病毒对疫苗临床试验、疫苗批准和大规模生产的响应时间可能会显着缩短。目前看来，从病毒发现到最终进入人们的怀抱大约需要9个月到一年的时间。最终，这个响应时间可能会缩短到几个月。</blockquote></p><p></p><p>Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.</p><p><blockquote>Omnicron 于 2021 年 11 月 24 日左右首次被确定为变体。Moderna 首席执行官 Stéphane Bancel 在接受 CNBC 采访时表示，Omnicron 疫苗的临床试验即将开始，Omnicron 疫苗应该会在秋季上市。这种对传染病的快速反应是以前闻所未闻的，随着时间的推移，mRNA平台公司不仅可以熟练地快速生产针对特定病毒的疫苗，还可以熟练地生产针对特定病毒株的疫苗，在世界上的特定地区。我认为 Moderna 正在世界不同国家和地区建设生产能力的原因之一是，疫苗最终将不再是适合所有国家的一刀切，而是更多地遵循区域生产基地的路线，为该特定地区最流行的病毒和病毒株生产特定疫苗。</blockquote></p><p>Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.</p><p><blockquote>mRNA平台的另一个潜在巨大优势是灵活性。理论上，mRNA制造工厂可以相对快速地切换到生产任何其他基于mRNA的药物。例如，生产新冠肺炎疫苗的mRNA工厂有可能迅速转向生产埃博拉疫苗。这与许多传统药物的制造过程形成鲜明对比，传统药物需要专门的工厂来生产药物。这可能会使生产多种不同类型药品的资本支出远低于传统药品制造商。</blockquote></p><p>The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.</p><p><blockquote>新冠肺炎疫情强调了改变疫苗是多么容易，只需将Moderna想要靶向的任何病毒的基因序列插入其基本mRNA平台。这不仅有助于攻击不同的新冠肺炎毒株，还意味着Moderna有能力使用任何病毒的序列，无论是流感、艾滋病毒、巨细胞病毒、结核病、寨卡病毒还是狂犬病，并快速生产出可供测试的疫苗。</blockquote></p><p><b>COVID-19 Progress</b></p><p><blockquote><b>新冠肺炎进展</b></blockquote></p><p>COVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.</p><p><blockquote>新冠肺炎在短短两年内彻底改变了Moderna的命运。直到2020年，Moderna只是一家鲜为人知的药物研究机构，收入很少，但作为第二家将预防新冠肺炎的可行疫苗引入美国市场的公司，Moderna在全球范围内广为人知，该公司已经建立了一个巨大的品牌，即将成为制药行业的巨头。</blockquote></p><p>There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:</p><p><blockquote>有现实世界的证据表明，到目前为止，Moderna已经生产出了最有效的新冠肺炎疫苗。来自世界各地的数据支持美国III期数据中显示的非常强的疗效。最近，新加坡公布的数据显示，新冠肺炎死亡率在服用Moderna的人中最低。新加坡有802人死亡，其中70%未接种疫苗。在Moderna、辉瑞-BioNTech、国药集团和科兴疫苗中，Moderna的死亡率最低：</blockquote></p><p><ul><li>11 deaths per 100,000: Sinovac</li><li>7.8 deaths per 100,000: Sinopharm</li><li>6.2 deaths per 100,000: Pfizer/BioNTech</li><li>1 death per 100,000: Moderna</li></ul>Over the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna&#39;s COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.</p><p><blockquote><ul><li>每10万人中有11人死亡：科兴</li><li>每10万人中有7.8人死亡：国药集团</li><li>每10万人中有6.2人死亡：辉瑞/BioNTech</li><li>每10万人中有1人死亡：现代</li></ul>2021 年期间，Moderna 向世界各地许多不同地点运送了 8.07 亿剂 Moderna 的 COVID-19 疫苗 Spikevax，其中约 25% 运往低收入和中等收入国家。Moderna最近在1月10日举行的摩根大通第40届年度医疗保健会议上报告称，2021年Spikevax产品销售额的初步估计约为175亿美元。</blockquote></p><p>Because of the huge demand for Moderna&#39;s vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.</p><p><blockquote>由于全球对 Moderna 疫苗的巨大需求，在 2021 年的相当一部分时间里，该公司受到供应限制，但这种情况现在开始好转。Moderna首席执行官Stephane Bancel将供应限制的原因归因于Moderna的剂量高于辉瑞-BioNTech疫苗。较高的剂量是对制造资源的巨大消耗。此后，Moderna 在 2021 年建立了额外的制造能力，现在能够更好地满足 COVID-19 的需求。第四季度，Moderna 出货量为 3 亿剂，运行速度为 12 亿剂。Moderna 相信，如有必要，他们可以在 2022 年生产 20 亿至 30 亿剂加强剂。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f41315e4b985027121aaf2dfca75dc71\" tg-width=\"640\" tg-height=\"356\" width=\"100%\" height=\"auto\"/><span>Moderna Spikevax advanced purchase agreements</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna Spikevax 高级采购协议</span></p></blockquote></p><p></p><p>Because COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (&#34;APA&#34;) and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of &#39;22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.</p><p><blockquote>由于 COVID-19 疫苗制造商最近不得不与新变种进行打地鼠游戏，因此对 Spikevax 的需求仍在上升。从上图可以看出，从11月4日到1月10日，Moderna额外获得了15亿美元的预先购买协议（“APA”）和5亿美元的期权，这些数字主要集中在上半年。Moderna仍在与许多国家就是否需要增加额外的疫苗进行讨论，以应对秋季进入2022年冬季的问题。我预计，当一切都结束后，Moderna 可能会在今年内签署更多 APA。因此，看起来2022年可能会再次成为Moderna的又一个辉煌的一年。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e1246421e026d6fd58bec48546a19260\" tg-width=\"640\" tg-height=\"362\" width=\"100%\" height=\"auto\"/><span>How COVID-19 is likely to evolve</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19 可能如何演变</span></p></blockquote></p><p>Currently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna&#39;s post pandemic plan to replace the likely COVID-19 vaccine declining revenues?</p><p><blockquote>目前，世界正处于变异再感染浪潮之中，这可能会持续到2022年，但到2023年，新冠肺炎应该会变得更具季节性和地方性。预计未来几年，发病率将越来越低，在一两年内，新冠肺炎很有可能会变得更像今天的流感。大流行后，新冠肺炎预计主要只影响50岁以上的人、医护人员、免疫功能低下的人和其他高危人群。这些群体可能需要加强剂，以确保他们不会患上严重疾病和住院治疗。随着 COVID-19 的结束，对 Spikevax 的需求可能会在 2023 年至 2024 年期间开始下降。这就是为什么有些人一直预测 Moderna 的收入会下降。那么，Moderna 在大流行后有什么计划来取代可能下降的 COVID-19 疫苗收入？</blockquote></p><p><b>Moderna&#39;s Plan Moving Forward</b></p><p><blockquote><b>Moderna 的前进计划</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9965c1224ac3e57e5a4c764bbb50975\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna Product Strategy in 2022</span></p><p><blockquote><p class=\"t-img-caption\"><span>2022年Moderna产品策略</span></p></blockquote></p><p>The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.</p><p><blockquote>Moderna计划应对新冠肺炎疫苗可能下降的最初方法是将不同的季节性呼吸道疫苗捆绑在一起，形成一种疫苗。获得新冠肺炎特定疫苗的日子似乎正在消失，泛呼吸道疫苗可能会非常有效地与任何后期进入市场的落后者竞争，只有新冠肺炎解决方案。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4995949c9a253ebe6663e2deeb5ccce3\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna vision for pan-respiratory vaccine</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna 泛呼吸道疫苗愿景</span></p></blockquote></p><p>Moderna&#39;s vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn&#39;t be surprised if a pan-respiratory vaccine starts to appear within two years.</p><p><blockquote>Moderna的愿景是，随着时间的推移，可以定制年度单剂量泛呼吸助推器，以适应不同的人口统计、不同的地理位置和不同的呼吸道疾病。最终，Moderna甚至希望针对特定地区的特定呼吸道疾病菌株。如果两年内出现泛呼吸道疫苗，我不会感到惊讶。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eb027ec45a0750fdcd8b65307c4008d1\" tg-width=\"640\" tg-height=\"359\" width=\"100%\" height=\"auto\"/><span>Moderna Strategy After COVID-19</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19 后的现代战略</span></p></blockquote></p><p>Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax&#39;s pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax&#39;s pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.</p><p><blockquote>与 Novavax（纳斯达克股票代码：NVAX）等公司的疫苗技术不同，mRNA 除了传染病之外，还可用于许多其他不同的用途。 Novavax 的产品线仅包括 9 个项目，针对 COVID-19 以外的 5 种其他传染病。Novavax的大部分管道主要涉及呼吸道疾病，只有一种直接接触潜伏病毒埃博拉出现在名单上。</blockquote></p><p>In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna&#39;s most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.</p><p><blockquote>相比之下，Moderna 在开发针对多种潜伏病毒的解决方案方面遥遥领先，这些病毒比埃博拉病毒更普遍。首批针对并已进入临床试验的是巨细胞病毒和EBV，艾滋病毒即将开始试验。CMV 是 Moderna 正在研发的最先进的药物，第一位患者已经在 III 期试验中接受了给药。除了巨细胞病毒、EBV和HIV，还有许多其他未公开的潜伏病毒正在实验室中研究。</blockquote></p><p></p><p>The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics&#39; engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won&#39;t go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics&#39; CAR-Macrophage&#39;s technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.</p><p><blockquote>Moderna优先考虑的下一个领域是使用mRNA技术开发疗法，这使得该公司能够生产肿瘤产品、心脏产品、罕见遗传疾病产品和自身免疫性疾病产品。对于 Moderna 来说，这是一个具有巨大优势的领域。Moderna将使用全新的方法来开发对抗癌症的解决方案，并为目前没有重要解决方案的疾病开发解决方案。最近，Moderna与Carisma Therapeutics建立了合作伙伴关系。Moderna计划将其mRNA技术与Carisma Therapeutics的工程巨噬细胞技术相结合，开发对抗实体瘤癌症的解决方案。这一点之所以重要，是因为虽然自体 CAR-T 在血红素恶性肿瘤（即血癌）中具有非常好的数据，但它们在实体瘤中并不是非常有效，80% 的癌症患者死于实体瘤。我不会深入探讨其背后的科学，但科学家们知道 CAR-T 对实体瘤效果不佳的原因，两家公司都认为 Carisma Therapeutics 的 CAR-巨噬细胞技术与 mRNA 技术相结合可以产生革命性的新方法，从根本上治愈最普遍和最难治疗的癌症死亡形式，即实体瘤。</blockquote></p><p>Moderna&#39;s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients&#39; own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.</p><p><blockquote>Moderna在mRNA和LNP技术方面的深厚专业知识为工程巨噬细胞开辟了一个潜在的改变游戏规则的机会。直接向单核细胞和巨噬细胞的体内递送实现了一种现成的治疗方法，该方法使用患者自己的细胞来提供真正个性化的治疗。资料来源：CarismaRight 总裁兼首席执行官 Steven Kelly 现在，没有办法考虑到 Moderna 可能开发出一种更好的解决方案来攻击并可能治愈实体瘤癌症的优势。像 Moderna 与 Carisma 合作的疗法可能会产生与 COVID-19 疫苗一样大的本垒打，如果不是更大的话。</blockquote></p><p>The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.</p><p><blockquote>Moderna正在开发使用基因编辑酶的解决方案的第四个领域。Moderna 最近才认真涉足基因编辑领域，当时该公司与 Metagenomi 签署了合作协议。对于那些不知道的人来说，基因编辑是 Editas（纳斯达克股票代码：EDIT）和 CRISPR Therapeutics（纳斯达克股票代码：CRSP）等公司正在追求的相同策略。宏基因组合作的重点将是严重的遗传疾病。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8041f6f8edad22795cbe4a3295d68973\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"/><span>Moderna capital allocation priorities</span></p><p><blockquote><p class=\"t-img-caption\"><span>现代资本配置优先事项</span></p></blockquote></p><p>Moderna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna&#39;s number one capital allocation priority is investing in R&amp;D, manufacturing infrastructure and continuing to build out the company&#39;s commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&amp;A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.</p><p><blockquote>Moderna 已经开始花费其来自 COVID-19 疫苗销售的巨额现金流。我只是想在本文中包含上面的幻灯片，因为它表明 Moderna 的首要资本配置优先事项是投资研发、制造基础设施并继续建设公司的商业基础设施。第二个优先事项是投资于外部投资机会，无论是以合作还是并购的形式。与Metagenomi和Carisma Therapeutics的合作是第二个优先事项的例子。</blockquote></p><p><b>Manufacturing Capacity</b></p><p><blockquote><b>生产能力</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36484ebc09cffbacbfa8ce06eea49f22\" tg-width=\"640\" tg-height=\"357\" width=\"100%\" height=\"auto\"/><span>Moderna In-country vaccine manufacturing</span></p><p><blockquote><p class=\"t-img-caption\"><span>现代国产疫苗生产</span></p></blockquote></p><p>There is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.</p><p><blockquote>Moderna 现有的潜在竞争对手相当多，还有印度等国家支持新兴的本土 mRNA 平台公司。Moderna 领先于竞争对手的方式之一是利用其 153 亿美元现金和第三季度末的 32 亿美元自由现金流，在全球范围内建立强大的 mRNA 制造能力。Moderna 已宣布与澳大利亚和加拿大达成原则协议，在这些国家建立 mRNA 疫苗制造厂。这些公告是对在非洲建立一个能够每年生产多达5亿剂疫苗的工厂的计划的补充。我相信 Moderna 仍在选择生产基地位于哪个非洲国家。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>The major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna&#39;s stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna&#39;s stock much lower.</p><p><blockquote>Moderna 短期内面临的主要风险是来自 COVID-19 的收入下降速度超过了 Moderna 将其他疫苗或疗法推向市场并显示出优异效果的速度。最接近批准的药物是巨细胞病毒疫苗。巨细胞病毒疫苗的批准可能会推高 Moderna 的股价，因为这将表明 mRNA 对于解决其他疾病是可行的。CMV 被拒绝可能会使 Moderna 的股价大幅下跌。</blockquote></p><p></p><p>Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.</p><p><blockquote>Moderna面临的另一个主要风险是专利纠纷和诉讼。Moderna 最近不得不在与 NIH 的 COVID-19 专利纠纷中做出让步，Moderna 还可能很快面临 Arbutus（纳斯达克股票代码：ABUS）就 COVID-19 疫苗提起的专利侵权诉讼。目前，尚不清楚这些纠纷将如何长期影响 Moderna。</blockquote></p><p><b>Analyst Price Targets</b></p><p><blockquote><b>分析师目标价</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0c0e5d79d00e415b16e4141b35eaaad4\" tg-width=\"461\" tg-height=\"416\" width=\"100%\" height=\"auto\"/><span>Moderna Analyst Price Targets</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna 分析师价格目标</span></p></blockquote></p><p>The above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.</p><p><blockquote>以上是基于 15 位华尔街分析师在过去 3 个月中为 Moderna 提供的 12 个月目标价。平均目标价为289.07美元，高预测为506.00美元，低预测为86.00美元。平均目标价较上次价格 210.17 美元上涨 38%。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/19ae061dd4c060bb37f43ff041dc2577\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据由YCharts提供</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ff983411a9b9571f66378eddc98653c\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据由YCharts提供</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/259a902789541a798fdf388cf46d6b37\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据由YCharts提供</span></p></blockquote></p><p>The comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.</p><p><blockquote>这三家相对较新的生物技术公司与已经发货的 COVID-19 疫苗之间的比较表明，Moderna 是估值最高的股票，但 BioNTech 的收入增长和营业利润率最好。严格按照价值来看，BioNTech 可能是最值得购买的，但实际上，这三家公司都是生物技术公司，其中一个热门产品或一个重大的惨淡失败可能会改变公司的命运。我认为这三家公司都非常投机，即使它们在为新冠肺炎疫情生产解决方案方面取得了成功。</blockquote></p><p>I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna&#39;s current valuation will be viewed in hindsight as being way too low. If most of Moderna&#39;s pipeline fails then the valuation will be viewed in hindsight as being way too high.</p><p><blockquote>我不太喜欢尝试对任何生物技术公司使用估值技术。根本无法评估许多生物技术公司下注的未来潜在成败。例如，如果 Moderna 是治愈实体瘤癌症的一部分，那么事后看来，Moderna 目前的估值将被视为过低。如果 Moderna 的大部分产品线失败，那么事后看来，估值将被视为过高。</blockquote></p><p><b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p>Moderna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.</p><p><blockquote>Moderna是一个高风险、高回报的赌注，押注mRNA技术成功预防或治愈许多难以治疗的疾病。这是一只严格适合有兴趣在五到十年时间内投机潜在全垒打类型产品的长期积极增长投资者的股票。新冠肺炎疫苗的效力如此之高，这在一定程度上缓解了Moderna只是一家单一产品公司的风险，这在一定程度上证明了mRNA平台可以产生解决其他疑难疾病的其他新方法。</blockquote></p><p>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna&#39;s stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.</p><p><blockquote>Moderna 的历史高点 497.49 美元回调 58%，让激进的成长型投资者有机会买入一家具有巨大潜在上涨空间的公司。然而，规避风险或对短期价格变动敏感的投资者目前应避开 Moderna 的股票，因为如果 COVID-19 收入下降过快，而 Moderna 能够证明它可以在解决其他疾病方面取得类似的成功，则存在重大下行风险。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格下的高上涨潜力</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna: High Upside Potential At Current Prices<blockquote>Moderna：当前价格下的高上涨潜力</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-17 17:42</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><b>Summary</b></p><p><blockquote><html><head></head><body><b>总结</b></body></html></blockquote></p><p><ul><li>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity.</li><li>Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.</li><li>Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.</li><li>One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.</li><li>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/466434ab0d3291095a83741482c15948\" tg-width=\"1536\" tg-height=\"1024\" width=\"100%\" height=\"auto\"/><span>Maddie Meyer/Getty Images News</span></p><p><blockquote><ul><li>Moderna 不仅通过开发 COVID-19 疫苗，而且通过扩大公司的 mRNA 制造能力，拥有显着的先发竞争优势。</li><li>Moderna 最近报告称，COVID-19 对 2021 年产品销售额的初步估计约为 175 亿美元。</li><li>最近，新加坡公布的数据显示，新冠肺炎死亡率是Moderna疫苗接种者中最低的。</li><li>Moderna 在潜在 mRNA 竞争中保持领先地位的方法之一是利用其 153 亿美元现金和 32 亿美元自由现金流继续在全球范围内建立强大的 mRNA 制造能力。</li><li>Moderna 的历史高点 497.49 美元回调 58%，让激进的成长型投资者有机会买入一家具有巨大上涨潜力的公司。</li></ul><p class=\"t-img-caption\"><span>麦迪·迈耶/盖蒂图片社新闻</span></p></blockquote></p><p>Moderna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world&#39;s most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.</p><p><blockquote>Moderna（纳斯达克股票代码：mRNA）作为开发世界上最先进的mRNA平台的先行者，具有极高的上涨空间。帮助预防或治愈人类已知的一些最棘手疾病的最有前途的潜在解决方案之一是mRNA技术，Moderna不仅开发了最先进的mRNA平台，还在全球范围内建立了强大的mRNA制造能力。有许多公司处于开发mRNA技术的不同阶段，但很少有公司像Moderna一样在开发mRNA技术以及拥有每年生产数十亿剂疫苗的制造能力和其他商业基础设施方面取得如此进展。目前，唯一拥有先进 mRNA 技术知识和制造能力与 Moderna 在同一舞台上竞争的公司是 BioNTech（纳斯达克股票代码：BNTX）-辉瑞（纽约证券交易所股票代码：PFE）合作伙伴关系。</blockquote></p><p>Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company&#39;s mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna&#39;s first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.</p><p><blockquote>Moderna 不仅通过开发 COVID-19 疫苗，而且通过扩大公司的 mRNA 制造能力，拥有显着的先发竞争优势。在实验室环境中生产mRNA是一回事，但在世界各地监管机构批准的生产基地安全地大规模生产有效疫苗则是另一回事。Moderna 的先发优势已转化为来自 COVID-19 销售的巨额现金，该公司可以通过投资推进 mRNA 技术、改进 mRNA 制造工艺以及在全球范围内建立强大的制造能力来进一步扩大其领先地位。Moderna 还在开发世界上最深的药物管道之一方面进展顺利。</blockquote></p><p>While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna&#39;s mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna&#39;s stock today.</p><p><blockquote>虽然先发优势并不完全是护城河，但至少在未来几年内，Moderna 应该在开发许多不同的基于 mRNA 的疗法或疫苗来治疗许多难以治疗的疾病方面享有显着的领先地位。Moderna 目前拥有 40 个不同的药物开发项目，这对于一家相对年轻的生物技术公司来说几乎是闻所未闻的，两年前它还只是一个研究机构。最终，Moderna 的 mRNA 平台和制造能力应该会为今天购买 Moderna 股票的投资者带来显着的长期上涨空间。</blockquote></p><p>Advantages of mRNA Technology</p><p><blockquote>mRNA技术的优势</blockquote></p><p>The reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.</p><p><blockquote>Moderna之所以能够快速开发出新冠肺炎解决方案，同时继续构建大量药物开发项目，是因为mRNA技术的本质。</blockquote></p><p>The development and manufacturing of mRNA for use as therapeutics<i>and</i>vaccines are comparatively simple, scalable<i>and</i>extremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people&#39;s arms. Eventually, this response time could shrink to matter of a few months.</p><p><blockquote>用作治疗剂的mRNA的开发和制造<i>和</i>疫苗相对简单，可扩展<i>和</i>极快。资料来源：Millapore Sigma mRNA 平台与传统药物制造相比具有许多优势。对新冠肺炎疫情的反应证明了mRNA平台的主要优势，即能够获取病毒序列，并在非常短的时间内快速从开发、临床试验、批准到疫苗的大规模生产。随着 Moderna 和其他公司获得更多经验，监管机构对 mRNA 技术更加满意，我可以预见未来有一天，发现毒性病毒对疫苗临床试验、疫苗批准和大规模生产的响应时间可能会显着缩短。目前看来，从病毒发现到最终进入人们的怀抱大约需要9个月到一年的时间。最终，这个响应时间可能会缩短到几个月。</blockquote></p><p></p><p>Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.</p><p><blockquote>Omnicron 于 2021 年 11 月 24 日左右首次被确定为变体。Moderna 首席执行官 Stéphane Bancel 在接受 CNBC 采访时表示，Omnicron 疫苗的临床试验即将开始，Omnicron 疫苗应该会在秋季上市。这种对传染病的快速反应是以前闻所未闻的，随着时间的推移，mRNA平台公司不仅可以熟练地快速生产针对特定病毒的疫苗，还可以熟练地生产针对特定病毒株的疫苗，在世界上的特定地区。我认为 Moderna 正在世界不同国家和地区建设生产能力的原因之一是，疫苗最终将不再是适合所有国家的一刀切，而是更多地遵循区域生产基地的路线，为该特定地区最流行的病毒和病毒株生产特定疫苗。</blockquote></p><p>Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.</p><p><blockquote>mRNA平台的另一个潜在巨大优势是灵活性。理论上，mRNA制造工厂可以相对快速地切换到生产任何其他基于mRNA的药物。例如，生产新冠肺炎疫苗的mRNA工厂有可能迅速转向生产埃博拉疫苗。这与许多传统药物的制造过程形成鲜明对比，传统药物需要专门的工厂来生产药物。这可能会使生产多种不同类型药品的资本支出远低于传统药品制造商。</blockquote></p><p>The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.</p><p><blockquote>新冠肺炎疫情强调了改变疫苗是多么容易，只需将Moderna想要靶向的任何病毒的基因序列插入其基本mRNA平台。这不仅有助于攻击不同的新冠肺炎毒株，还意味着Moderna有能力使用任何病毒的序列，无论是流感、艾滋病毒、巨细胞病毒、结核病、寨卡病毒还是狂犬病，并快速生产出可供测试的疫苗。</blockquote></p><p><b>COVID-19 Progress</b></p><p><blockquote><b>新冠肺炎进展</b></blockquote></p><p>COVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.</p><p><blockquote>新冠肺炎在短短两年内彻底改变了Moderna的命运。直到2020年，Moderna只是一家鲜为人知的药物研究机构，收入很少，但作为第二家将预防新冠肺炎的可行疫苗引入美国市场的公司，Moderna在全球范围内广为人知，该公司已经建立了一个巨大的品牌，即将成为制药行业的巨头。</blockquote></p><p>There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:</p><p><blockquote>有现实世界的证据表明，到目前为止，Moderna已经生产出了最有效的新冠肺炎疫苗。来自世界各地的数据支持美国III期数据中显示的非常强的疗效。最近，新加坡公布的数据显示，新冠肺炎死亡率在服用Moderna的人中最低。新加坡有802人死亡，其中70%未接种疫苗。在Moderna、辉瑞-BioNTech、国药集团和科兴疫苗中，Moderna的死亡率最低：</blockquote></p><p><ul><li>11 deaths per 100,000: Sinovac</li><li>7.8 deaths per 100,000: Sinopharm</li><li>6.2 deaths per 100,000: Pfizer/BioNTech</li><li>1 death per 100,000: Moderna</li></ul>Over the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna&#39;s COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.</p><p><blockquote><ul><li>每10万人中有11人死亡：科兴</li><li>每10万人中有7.8人死亡：国药集团</li><li>每10万人中有6.2人死亡：辉瑞/BioNTech</li><li>每10万人中有1人死亡：现代</li></ul>2021 年期间，Moderna 向世界各地许多不同地点运送了 8.07 亿剂 Moderna 的 COVID-19 疫苗 Spikevax，其中约 25% 运往低收入和中等收入国家。Moderna最近在1月10日举行的摩根大通第40届年度医疗保健会议上报告称，2021年Spikevax产品销售额的初步估计约为175亿美元。</blockquote></p><p>Because of the huge demand for Moderna&#39;s vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.</p><p><blockquote>由于全球对 Moderna 疫苗的巨大需求，在 2021 年的相当一部分时间里，该公司受到供应限制，但这种情况现在开始好转。Moderna首席执行官Stephane Bancel将供应限制的原因归因于Moderna的剂量高于辉瑞-BioNTech疫苗。较高的剂量是对制造资源的巨大消耗。此后，Moderna 在 2021 年建立了额外的制造能力，现在能够更好地满足 COVID-19 的需求。第四季度，Moderna 出货量为 3 亿剂，运行速度为 12 亿剂。Moderna 相信，如有必要，他们可以在 2022 年生产 20 亿至 30 亿剂加强剂。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f41315e4b985027121aaf2dfca75dc71\" tg-width=\"640\" tg-height=\"356\" width=\"100%\" height=\"auto\"/><span>Moderna Spikevax advanced purchase agreements</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna Spikevax 高级采购协议</span></p></blockquote></p><p></p><p>Because COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (&#34;APA&#34;) and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of &#39;22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.</p><p><blockquote>由于 COVID-19 疫苗制造商最近不得不与新变种进行打地鼠游戏，因此对 Spikevax 的需求仍在上升。从上图可以看出，从11月4日到1月10日，Moderna额外获得了15亿美元的预先购买协议（“APA”）和5亿美元的期权，这些数字主要集中在上半年。Moderna仍在与许多国家就是否需要增加额外的疫苗进行讨论，以应对秋季进入2022年冬季的问题。我预计，当一切都结束后，Moderna 可能会在今年内签署更多 APA。因此，看起来2022年可能会再次成为Moderna的又一个辉煌的一年。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e1246421e026d6fd58bec48546a19260\" tg-width=\"640\" tg-height=\"362\" width=\"100%\" height=\"auto\"/><span>How COVID-19 is likely to evolve</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19 可能如何演变</span></p></blockquote></p><p>Currently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna&#39;s post pandemic plan to replace the likely COVID-19 vaccine declining revenues?</p><p><blockquote>目前，世界正处于变异再感染浪潮之中，这可能会持续到2022年，但到2023年，新冠肺炎应该会变得更具季节性和地方性。预计未来几年，发病率将越来越低，在一两年内，新冠肺炎很有可能会变得更像今天的流感。大流行后，新冠肺炎预计主要只影响50岁以上的人、医护人员、免疫功能低下的人和其他高危人群。这些群体可能需要加强剂，以确保他们不会患上严重疾病和住院治疗。随着 COVID-19 的结束，对 Spikevax 的需求可能会在 2023 年至 2024 年期间开始下降。这就是为什么有些人一直预测 Moderna 的收入会下降。那么，Moderna 在大流行后有什么计划来取代可能下降的 COVID-19 疫苗收入？</blockquote></p><p><b>Moderna&#39;s Plan Moving Forward</b></p><p><blockquote><b>Moderna 的前进计划</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a9965c1224ac3e57e5a4c764bbb50975\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna Product Strategy in 2022</span></p><p><blockquote><p class=\"t-img-caption\"><span>2022年Moderna产品策略</span></p></blockquote></p><p>The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.</p><p><blockquote>Moderna计划应对新冠肺炎疫苗可能下降的最初方法是将不同的季节性呼吸道疫苗捆绑在一起，形成一种疫苗。获得新冠肺炎特定疫苗的日子似乎正在消失，泛呼吸道疫苗可能会非常有效地与任何后期进入市场的落后者竞争，只有新冠肺炎解决方案。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4995949c9a253ebe6663e2deeb5ccce3\" tg-width=\"640\" tg-height=\"360\" width=\"100%\" height=\"auto\"/><span>Moderna vision for pan-respiratory vaccine</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna 泛呼吸道疫苗愿景</span></p></blockquote></p><p>Moderna&#39;s vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn&#39;t be surprised if a pan-respiratory vaccine starts to appear within two years.</p><p><blockquote>Moderna的愿景是，随着时间的推移，可以定制年度单剂量泛呼吸助推器，以适应不同的人口统计、不同的地理位置和不同的呼吸道疾病。最终，Moderna甚至希望针对特定地区的特定呼吸道疾病菌株。如果两年内出现泛呼吸道疫苗，我不会感到惊讶。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/eb027ec45a0750fdcd8b65307c4008d1\" tg-width=\"640\" tg-height=\"359\" width=\"100%\" height=\"auto\"/><span>Moderna Strategy After COVID-19</span></p><p><blockquote><p class=\"t-img-caption\"><span>COVID-19 后的现代战略</span></p></blockquote></p><p>Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax&#39;s pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax&#39;s pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.</p><p><blockquote>与 Novavax（纳斯达克股票代码：NVAX）等公司的疫苗技术不同，mRNA 除了传染病之外，还可用于许多其他不同的用途。 Novavax 的产品线仅包括 9 个项目，针对 COVID-19 以外的 5 种其他传染病。Novavax的大部分管道主要涉及呼吸道疾病，只有一种直接接触潜伏病毒埃博拉出现在名单上。</blockquote></p><p>In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna&#39;s most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.</p><p><blockquote>相比之下，Moderna 在开发针对多种潜伏病毒的解决方案方面遥遥领先，这些病毒比埃博拉病毒更普遍。首批针对并已进入临床试验的是巨细胞病毒和EBV，艾滋病毒即将开始试验。CMV 是 Moderna 正在研发的最先进的药物，第一位患者已经在 III 期试验中接受了给药。除了巨细胞病毒、EBV和HIV，还有许多其他未公开的潜伏病毒正在实验室中研究。</blockquote></p><p></p><p>The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics&#39; engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won&#39;t go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics&#39; CAR-Macrophage&#39;s technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.</p><p><blockquote>Moderna优先考虑的下一个领域是使用mRNA技术开发疗法，这使得该公司能够生产肿瘤产品、心脏产品、罕见遗传疾病产品和自身免疫性疾病产品。对于 Moderna 来说，这是一个具有巨大优势的领域。Moderna将使用全新的方法来开发对抗癌症的解决方案，并为目前没有重要解决方案的疾病开发解决方案。最近，Moderna与Carisma Therapeutics建立了合作伙伴关系。Moderna计划将其mRNA技术与Carisma Therapeutics的工程巨噬细胞技术相结合，开发对抗实体瘤癌症的解决方案。这一点之所以重要，是因为虽然自体 CAR-T 在血红素恶性肿瘤（即血癌）中具有非常好的数据，但它们在实体瘤中并不是非常有效，80% 的癌症患者死于实体瘤。我不会深入探讨其背后的科学，但科学家们知道 CAR-T 对实体瘤效果不佳的原因，两家公司都认为 Carisma Therapeutics 的 CAR-巨噬细胞技术与 mRNA 技术相结合可以产生革命性的新方法，从根本上治愈最普遍和最难治疗的癌症死亡形式，即实体瘤。</blockquote></p><p>Moderna&#39;s deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients&#39; own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.</p><p><blockquote>Moderna在mRNA和LNP技术方面的深厚专业知识为工程巨噬细胞开辟了一个潜在的改变游戏规则的机会。直接向单核细胞和巨噬细胞的体内递送实现了一种现成的治疗方法，该方法使用患者自己的细胞来提供真正个性化的治疗。资料来源：CarismaRight 总裁兼首席执行官 Steven Kelly 现在，没有办法考虑到 Moderna 可能开发出一种更好的解决方案来攻击并可能治愈实体瘤癌症的优势。像 Moderna 与 Carisma 合作的疗法可能会产生与 COVID-19 疫苗一样大的本垒打，如果不是更大的话。</blockquote></p><p>The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.</p><p><blockquote>Moderna正在开发使用基因编辑酶的解决方案的第四个领域。Moderna 最近才认真涉足基因编辑领域，当时该公司与 Metagenomi 签署了合作协议。对于那些不知道的人来说，基因编辑是 Editas（纳斯达克股票代码：EDIT）和 CRISPR Therapeutics（纳斯达克股票代码：CRSP）等公司正在追求的相同策略。宏基因组合作的重点将是严重的遗传疾病。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8041f6f8edad22795cbe4a3295d68973\" tg-width=\"640\" tg-height=\"361\" width=\"100%\" height=\"auto\"/><span>Moderna capital allocation priorities</span></p><p><blockquote><p class=\"t-img-caption\"><span>现代资本配置优先事项</span></p></blockquote></p><p>Moderna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna&#39;s number one capital allocation priority is investing in R&amp;D, manufacturing infrastructure and continuing to build out the company&#39;s commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&amp;A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.</p><p><blockquote>Moderna 已经开始花费其来自 COVID-19 疫苗销售的巨额现金流。我只是想在本文中包含上面的幻灯片，因为它表明 Moderna 的首要资本配置优先事项是投资研发、制造基础设施并继续建设公司的商业基础设施。第二个优先事项是投资于外部投资机会，无论是以合作还是并购的形式。与Metagenomi和Carisma Therapeutics的合作是第二个优先事项的例子。</blockquote></p><p><b>Manufacturing Capacity</b></p><p><blockquote><b>生产能力</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/36484ebc09cffbacbfa8ce06eea49f22\" tg-width=\"640\" tg-height=\"357\" width=\"100%\" height=\"auto\"/><span>Moderna In-country vaccine manufacturing</span></p><p><blockquote><p class=\"t-img-caption\"><span>现代国产疫苗生产</span></p></blockquote></p><p>There is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.</p><p><blockquote>Moderna 现有的潜在竞争对手相当多，还有印度等国家支持新兴的本土 mRNA 平台公司。Moderna 领先于竞争对手的方式之一是利用其 153 亿美元现金和第三季度末的 32 亿美元自由现金流，在全球范围内建立强大的 mRNA 制造能力。Moderna 已宣布与澳大利亚和加拿大达成原则协议，在这些国家建立 mRNA 疫苗制造厂。这些公告是对在非洲建立一个能够每年生产多达5亿剂疫苗的工厂的计划的补充。我相信 Moderna 仍在选择生产基地位于哪个非洲国家。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>The major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna&#39;s stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna&#39;s stock much lower.</p><p><blockquote>Moderna 短期内面临的主要风险是来自 COVID-19 的收入下降速度超过了 Moderna 将其他疫苗或疗法推向市场并显示出优异效果的速度。最接近批准的药物是巨细胞病毒疫苗。巨细胞病毒疫苗的批准可能会推高 Moderna 的股价，因为这将表明 mRNA 对于解决其他疾病是可行的。CMV 被拒绝可能会使 Moderna 的股价大幅下跌。</blockquote></p><p></p><p>Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.</p><p><blockquote>Moderna面临的另一个主要风险是专利纠纷和诉讼。Moderna 最近不得不在与 NIH 的 COVID-19 专利纠纷中做出让步，Moderna 还可能很快面临 Arbutus（纳斯达克股票代码：ABUS）就 COVID-19 疫苗提起的专利侵权诉讼。目前，尚不清楚这些纠纷将如何长期影响 Moderna。</blockquote></p><p><b>Analyst Price Targets</b></p><p><blockquote><b>分析师目标价</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0c0e5d79d00e415b16e4141b35eaaad4\" tg-width=\"461\" tg-height=\"416\" width=\"100%\" height=\"auto\"/><span>Moderna Analyst Price Targets</span></p><p><blockquote><p class=\"t-img-caption\"><span>Moderna 分析师价格目标</span></p></blockquote></p><p>The above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.</p><p><blockquote>以上是基于 15 位华尔街分析师在过去 3 个月中为 Moderna 提供的 12 个月目标价。平均目标价为289.07美元，高预测为506.00美元，低预测为86.00美元。平均目标价较上次价格 210.17 美元上涨 38%。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/19ae061dd4c060bb37f43ff041dc2577\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据由YCharts提供</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4ff983411a9b9571f66378eddc98653c\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据由YCharts提供</span></p></blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/259a902789541a798fdf388cf46d6b37\" tg-width=\"635\" tg-height=\"450\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><blockquote><p class=\"t-img-caption\"><span>数据由YCharts提供</span></p></blockquote></p><p>The comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.</p><p><blockquote>这三家相对较新的生物技术公司与已经发货的 COVID-19 疫苗之间的比较表明，Moderna 是估值最高的股票，但 BioNTech 的收入增长和营业利润率最好。严格按照价值来看，BioNTech 可能是最值得购买的，但实际上，这三家公司都是生物技术公司，其中一个热门产品或一个重大的惨淡失败可能会改变公司的命运。我认为这三家公司都非常投机，即使它们在为新冠肺炎疫情生产解决方案方面取得了成功。</blockquote></p><p>I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna&#39;s current valuation will be viewed in hindsight as being way too low. If most of Moderna&#39;s pipeline fails then the valuation will be viewed in hindsight as being way too high.</p><p><blockquote>我不太喜欢尝试对任何生物技术公司使用估值技术。根本无法评估许多生物技术公司下注的未来潜在成败。例如，如果 Moderna 是治愈实体瘤癌症的一部分，那么事后看来，Moderna 目前的估值将被视为过低。如果 Moderna 的大部分产品线失败，那么事后看来，估值将被视为过高。</blockquote></p><p><b>Conclusion</b></p><p><blockquote><b>结论</b></blockquote></p><p>Moderna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.</p><p><blockquote>Moderna是一个高风险、高回报的赌注，押注mRNA技术成功预防或治愈许多难以治疗的疾病。这是一只严格适合有兴趣在五到十年时间内投机潜在全垒打类型产品的长期积极增长投资者的股票。新冠肺炎疫苗的效力如此之高，这在一定程度上缓解了Moderna只是一家单一产品公司的风险，这在一定程度上证明了mRNA平台可以产生解决其他疑难疾病的其他新方法。</blockquote></p><p>The 58% pullback from Moderna&#39;s all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna&#39;s stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.</p><p><blockquote>Moderna 的历史高点 497.49 美元回调 58%，让激进的成长型投资者有机会买入一家具有巨大潜在上涨空间的公司。然而，规避风险或对短期价格变动敏感的投资者目前应避开 Moderna 的股票，因为如果 COVID-19 收入下降过快，而 Moderna 能够证明它可以在解决其他疾病方面取得类似的成功，则存在重大下行风险。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://seekingalpha.com/article/4479930-moderna-high-upside-potential-at-current-prices","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131862461","content_text":"SummaryModerna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity.Moderna recently reported the preliminary COVID-19 estimate for product sales in 2021 as being approximately $17.5 billion.Recently, Singapore released data showing that COVID-19 deaths were the lowest among Moderna vaccine takers.One of the ways that Moderna is keeping ahead of potential mRNA competition is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow to continue building out significant mRNA manufacturing capability across the world.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant upside potential.Maddie Meyer/Getty Images NewsModerna (NASDAQ:MRNA) has extremely high upside from being a first mover in developing the world's most advanced mRNA platform. One of the most promising potential solutions for helping prevent or cure some of the most intractable diseases known to man is mRNA technology and Moderna has not only developed the most advanced mRNA platform but has also built out significant mRNA manufacturing capacity worldwide. There are many companies that are in various stages of developing mRNA technology but there are very few that have advanced as far as Moderna has in both developing mRNA technology, as well as having the manufacturing capacity and other commercial infrastructure to produce billions of doses of a vaccine per year. At this time, the only companies that have both the knowledge of advanced mRNA techniques and the manufacturing capacity to compete in the same arena as Moderna is the BioNTech (NASDAQ:BNTX) - Pfizer (NYSE:PFE) partnership.Moderna has a significant first mover competitive advantage by not only developing the COVID-19 vaccine but also by scaling the company's mRNA manufacturing capacity. It is one thing to produce mRNA in a lab setting but quite another to safely mass produce effective vaccines in regulator approved manufacturing sites around the world. Moderna's first mover advantage has translated into a very large war chest of cash from COVID-19 sales in which the company can use to further its lead by investing in advancing mRNA technology, improving mRNA manufacturing processes, and building out significant manufacturing capability worldwide. Moderna is also well along in developing one of the deepest drug pipelines in the world.While a first mover advantage is not exactly a moat, for the next several years at least, Moderna should enjoy a significant lead in developing many different mRNA-based therapies or vaccines to treat numerous difficult to treat diseases. Moderna currently has 40 different drug development programs, which is almost unheard of for such a relatively young biotech company that only two years ago was simply a research outfit. In the end, Moderna's mRNA platform and manufacturing capacity should result in significant long-term upside for investors buying into Moderna's stock today.Advantages of mRNA TechnologyThe reason why Moderna was able to rapidly develop a COVID-19 solution, while at the same time continuing to build out a significant number of drug development programs is because of the nature of mRNA technology.The development and manufacturing of mRNA for use as therapeuticsandvaccines are comparatively simple, scalableandextremely rapid.Source:Millapore SigmaThere are numerous advantages of a mRNA platform over traditional drug making. The major advantages of a mRNA platform that were demonstrated by the response to the COVID-19 pandemic was the ability to take the sequence of the virus and quickly move from development, to clinical trials, to approval, to mass manufacturing of a vaccine in a very rapid period of time. As Moderna and others get more experience and regulatory bodies get more comfortable with mRNA technology, I can see the day in the future where the response time of discovery of a virulent virus to clinical trials of a vaccine, to vaccine approval, to mass manufacturing of the vaccine could significantly shrink. Right now, it looks like it takes about 9 months to a year to move from virus discovery to eventually making it into people's arms. Eventually, this response time could shrink to matter of a few months.Omnicron was first identified as a variant around November 24, 2021. Moderna CEO Stéphane Bancel said in a CNBC interview that clinical trials for an Omnicron vaccine will start soon and a Omnicron vaccine should be available by fall. This type of rapid response to infectious diseases is unheard of before now and as time goes along, mRNA platform companies could not only become proficient in rapidly producing vaccines against specific viruses but also become proficient at producing vaccines against specific strains of a virus, in specific regions of the world. Among the reason why I think Moderna is building manufacturing capacity in different countries and regions of the world is because vaccines will eventually be less of a one size fits all countries and be more along the lines of regional manufacturing sites creating vaccines specific for the most prevalent viruses and strains of virus in that specific region.Another potential huge advantage of a mRNA platform is flexibility. Theoretically, a mRNA manufacturing plant can be relatively rapidly switched to producing any other mRNA-based drug. It is possible that a mRNA plant that makes COVID-19 vaccines could be rapidly switched to making an Ebola vaccine, for instance. This is in contrast to the manufacturing process of many traditional drugs that require a dedicated plant to produce a drug. This could make the CapEx involved for producing multiple different types of drugs, far lower than a traditional drug manufacturer.The COVID-19 pandemic has highlighted exactly how easy it is to change the vaccine simply by plugging the genetic sequence of any virus that Moderna wants to target right into its basic mRNA platform. This is not only useful for being able to attack different strains of COVID-19 but also means that Moderna has the ability of using the sequence of any virus whether that be the flu, HIV, CMV, Tuberculosis, Zika, or Rabies and quickly produce a vaccine ready for testing.COVID-19 ProgressCOVID-19 has totally changed the fortunes of Moderna within just two years. Up until 2020, Moderna was only a little-known drug research outfit that had very little revenues but being the second company to bring a viable vaccine to protect against COVID-19 into US markets, has made Moderna very widely known worldwide and the company has built a huge brand that is on the verge of becoming a giant within the drug industry.There is real world evidence that up until now, Moderna has produced the most effective COVID-19 vaccine. Data from all over the world supports the very strong efficacy that was shown in phase III data in the USA. Recently, Singapore released data showing that COVID-19 deaths were lowest among Moderna takers. Singapore had 802 deaths out of which 70% were unvaccinated. Between Moderna, Pfizer-BioNTech, Sinopharm and Sinovac vaccines, Moderna had the least death rates:11 deaths per 100,000: Sinovac7.8 deaths per 100,000: Sinopharm6.2 deaths per 100,000: Pfizer/BioNTech1 death per 100,000: ModernaOver the course of 2021, Moderna shipped 807 million doses of Spikevax, Moderna's COVID-19 vaccine, to many different locations around the world, with around 25% of those doses going to low-income and middle-income countries. Moderna reported recently during the JPMorgan 40th Annual Healthcare Conference on January 10th, that the preliminary estimate for Spikevax product sales in 2021 is around $17.5 billion.Because of the huge demand for Moderna's vaccine worldwide, for a decent part of 2021, the company was supply constrained but that situation is beginning to turn around now. Moderna CEO Stephane Bancel attributes the reason for supply constraints as Moderna having a higher dose than the Pfizer-BioNTech vaccine. The higher dose was a big drain on manufacturing resources. Moderna has since built out additional manufacturing capacity over the course of 2021 and is now in much better shape to address COVID-19 demand. In Q4, Moderna shipped 300 million doses, which is a run rate of 1.2 billion doses. Moderna believes that they can produce two billion to three billion doses of boosters over the course of 2022, if necessary.Moderna Spikevax advanced purchase agreementsBecause COVID-19 vaccine makers have lately been having to play whack-a-mole with new variants, the demand for Spikevax is still rising. As can be seen from the above graphic, from November 4th to January 10th, Moderna has gained and additional $1.5 billion in advanced purchase agreements (\"APA\") and $0.5 Billion in options, with those numbers being mostly heavily weighted toward the first half of the year. Moderna is still having ongoing discussions with many countries about whether additional vaccines will need to be added to address the fall moving into winter of '22. I expect that when all is said and done, Moderna could wind up signing additional APAs over the course of the year. So, it looks like 2022 might again be another banner year for Moderna.How COVID-19 is likely to evolveCurrently, the world is in the midst of variant reinfection waves, which will likely continue throughout 2022 but by 2023 COVID-19 should become more seasonal and endemic. Morbidity waves are expected to become lower and lower over the next several years and there is a good chance that COVID-19 will be seen more like the flu is perceived today within a year or two. Post-pandemic, COVID-19 is expected to mostly only affect people aged 50-plus, health care workers, immunocompromised people and other high-risk populations. These groups will likely need boosters to ensure that they do not get severe disease and hospitalization. As COVID-19 winds down, demand for Spikevax will probably begin dropping in the 2023-to-2024-time frame. This is why some people have been predicting revenue declines for Moderna. Well, what is Moderna's post pandemic plan to replace the likely COVID-19 vaccine declining revenues?Moderna's Plan Moving ForwardModerna Product Strategy in 2022The initial way that Moderna plans on countering the likely COVID-19 vaccine decline is by bundling different seasonal respiratory vaccines together into just one vaccine. The days of getting COVID-19 specific vaccine seem to be waning and a pan-respiratory vaccine will likely compete extremely effectively with any laggards coming to the market late with only a COVID-19 solution.Moderna vision for pan-respiratory vaccineModerna's vision is that an annual single-dose pan-respiratory booster can be customized to fit different demographics, different geographies, and different respiratory diseases over time. Eventually, Moderna even expects to target specific strains of respiratory diseases in specific regions. I wouldn't be surprised if a pan-respiratory vaccine starts to appear within two years.Moderna Strategy After COVID-19Unlike vaccine technology from companies like Novavax (NASDAQ:NVAX), mRNA can be used for many other different purposes besides infectious diseases.Novavax's pipeline only consists of 9 programs that target 5 other infectious diseases other than COVID-19. Most of Novavax's pipeline is mostly concerned with respiratory diseases, with only one direct contact latent virus, Ebola, appearing on the list.In contrast, Moderna is much further ahead in developing solutions against multiple latent viruses that are a lot more prevalent than Ebola. The first ones being targeted and are already in clinical trials are CMV and EBV, with HIV soon to begin trials. CMV is Moderna's most advanced drug in the pipeline and the first patient has already been dosed in phase III trials. Besides CMV, EBV, and HIV, there a many other undisclosed latent viruses being worked on in the labs.The next area that Moderna is prioritizing is in developing therapeutics using mRNA technology which allows the company to produce oncology products, cardio products, rare genetic disease products and autoimmune disease products. This is an area that has significant upside for Moderna. Moderna will be using totally new approaches to develop solutions against cancer and develop solutions for diseases that currently have no significant solutions. Recently, Moderna formed a partnership with Carisma Therapeutics. Moderna plans to combine its mRNA technology with Carisma Therapeutics' engineered macrophage technology to develop solutions against solid tumor cancer. The reason why this is important is because while autologous CAR-Ts have really good data in Heme malignancies, which are blood cancers, they have not been very effective in solid tumors and eighty percent of cancer patients die of solid tumors. I won't go deep into the science behind it but scientist know the reasons why CAR-Ts are not as effective with solid tumors, and both companies think Carisma Therapeutics' CAR-Macrophage's technology combined with mRNA technology can produce revolutionary new ways to essentially cure the most prevalent and difficult to treat form of cancer deaths which are solid tumors.Moderna's deep expertise in mRNA and LNP technologies opens up a potentially game-changing opportunity for engineered macrophages. In vivo delivery directly to monocytes and macrophages enables an off-the-shelf therapeutic approach that uses the patients' own cells to provide a truly personalized treatment.Source: Steven Kelly, President and Chief Executive Officer of CarismaRight now, there is no way to factor in the upside of Moderna potentially developing a significantly better solution to attacking and possibly curing solid tumor cancer. The therapies that could come out of partnerships like the one Moderna has with Carisma could potentially produce home runs just as big, if not bigger than the COVID-19 vaccine.The fourth area that Moderna is developing solutions using gene-editing enzymes. Moderna has only seriously got into gene editing relatively recently when the company signed a collaboration with Metagenomi. For those unaware,gene-editing is the same strategy that companies like Editas (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are pursuing. The focus for the Metagenomi collaboration will be on serious genetic diseases.Moderna capital allocation prioritiesModerna has already started spending its huge cash flows derived from COVID-19 vaccine sales. I just wanted to include the above slide in this article because it shows that Moderna's number one capital allocation priority is investing in R&D, manufacturing infrastructure and continuing to build out the company's commercial infrastructure. The second priority is investing in external investment opportunities, either in the form of collaborations or M&A. The collaborations with Metagenomi and Carisma Therapeutics are examples of this second priority.Manufacturing CapacityModerna In-country vaccine manufacturingThere is a rather large set of existing potential competitors to Moderna and there are also countries like India that are supporting rising home-grown mRNA platform companies. One of the ways that Moderna is keeping ahead of such efforts from competitors is using its $15.3 billion in cash and $3.2 billion in Free Cash Flow at the end of Q3, to build out significant mRNA manufacturing capability across the world. Moderna has announced in principle agreements with Australia and Canadato build out mRNA vaccine manufacturing plants within those countries. These announcements are in addition to the plans to build a factory capable of producing up to 500 million vaccine doses in Africa each year. I believe Moderna is still in the process of choosing which African country the manufacturing site will be located in.RisksThe major risk that Moderna faces in the short term is revenue from the COVID-19 declining faster than Moderna can get other vaccines or therapies on to market and show superior results. The closest drug to approval is a CMV vaccine. An approval of the CMV vaccine would likely shoot Moderna's stock higher because it would show that mRNA is viable for addressing other diseases. A CMV rejection would likely drop Moderna's stock much lower.Another major risk for Moderna are patent disputes and lawsuits. Moderna recently had to back down in a dispute with the NIH over COVID-19 patents and Moderna could also soon face a patent infringement lawsuit from Arbutus (NASDAQ:ABUS) over the COVID-19 vaccine. Currently, it is unknown how these disputes will impact Moderna over the longer term.Analyst Price TargetsModerna Analyst Price TargetsThe above is based on 15 Wall Street analysts offering 12-month price targets for Moderna in the last 3 months. The average price target is $289.07 with a high forecast of $506.00 and a low forecast of $86.00. The average price target represents a 38% increase from the last price of $210.17.ValuationData by YChartsData by YChartsData by YChartsThe comparisons between these three relatively new biotechs with COVID-19 vaccines already shipping, shows Moderna is the most highly valued stock but BioNTech has the best revenue growth and operating margins. Going strictly by value, BioNTech is probably the best buy but in reality, all three companies are biotechs, in which one hit product or one large dismal failure can change the fortunes of the company. I view all three companies as very speculative, even with the success achieved by producing solutions for the COVID-19 pandemic.I am not a big fan of trying to use valuation techniques on any biotech company. There is simply no way to value the future potential success or failure of the bets that many biotech companies make. If Moderna is part of curing solid tumor cancer, for instance, Moderna's current valuation will be viewed in hindsight as being way too low. If most of Moderna's pipeline fails then the valuation will be viewed in hindsight as being way too high.ConclusionModerna is a high risk, high reward bet on mRNA technology succeeding in either preventing or curing many difficult to treat diseases. This is a stock that is strictly for long-term aggressive growth investors that are interested in speculating on potential home-run type products over a five-to-ten-year time frame. The risk that Moderna is only a one-product company is somewhat mitigated by the fact that the efficacy of the COVID-19 vaccine was so high, that is serves as a kind of proof of concept that a mRNA platform can produce other novel ways of addressing other difficult diseases.The 58% pullback from Moderna's all-time high of $497.49 gives aggressive growth investors a chance to buy into a company with significant potential upside. However, risk averse or investors sensitive to short-term price movements should avoid Moderna's stock for now because there is significant downside risk if COVID-19 revenue drops off too rapidly before Moderna can show that it can achieve similar success in addressing other diseases.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2728,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698891874,"gmtCreate":1640331386141,"gmtModify":1640331634599,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"It's always the up and down&nbsp;","listText":"It's always the up and down&nbsp;","text":"It's always the up and down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698891874","repostId":"2193078140","repostType":4,"isVote":1,"tweetType":1,"viewCount":4592,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693469990,"gmtCreate":1640063725361,"gmtModify":1640064058108,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Should start positioning at 86. 70 is too bearish&nbsp;","listText":"Should start positioning at 86. 70 is too bearish&nbsp;","text":"Should start positioning at 86. 70 is too bearish","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693469990","repostId":"1180317442","repostType":4,"isVote":1,"tweetType":1,"viewCount":3540,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699267737,"gmtCreate":1639815129172,"gmtModify":1639815129921,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Semicon industry nvr die","listText":"Semicon industry nvr die","text":"Semicon industry nvr die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699267737","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","kind":"news","pubTimestamp":1639806035,"share":"https://www.laohunote.com/m/news/1161245886?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>韦德布什证券董事总经理丹·艾夫斯建议投资者坚持投资科技股，尽管美联储加息可能会出现潜在的估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是放弃科技的时候，”他周五对 CNBC 表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">缩放器</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技下行趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的巨额支出以及进一步向云迁移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内增加 2 万亿美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须对投资组合进行选择性，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从疫情中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA 在 2021 年的表现是迄今为止最好的，一年内上涨了一倍多。ZS 和 PANW 均上涨近 50%。AAPL 落后于规模较小的竞争对手，尽管它在 2021 年上涨了约 30%。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团中主要落后的是CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-18 13:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>韦德布什证券董事总经理丹·艾夫斯建议投资者坚持投资科技股，尽管美联储加息可能会出现潜在的估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是放弃科技的时候，”他周五对 CNBC 表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">缩放器</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技下行趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的巨额支出以及进一步向云迁移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内增加 2 万亿美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须对投资组合进行选择性，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从疫情中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA 在 2021 年的表现是迄今为止最好的，一年内上涨了一倍多。ZS 和 PANW 均上涨近 50%。AAPL 落后于规模较小的竞争对手，尽管它在 2021 年上涨了约 30%。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团中主要落后的是CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CYBR":"Cyber-Ark Software","ZS":"Zscaler Inc.","PANW":"Palo Alto Networks","NVDA":"英伟达"},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1,"symbols_score_info":{"PANW":0.9,"ZS":0.9,"NVDA":0.9,"CYBR":0.9}},"isVote":1,"tweetType":1,"viewCount":4935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877922815,"gmtCreate":1637881319600,"gmtModify":1637881319742,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"Will it ? Well market is insane, anything can happen [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877922815","repostId":"2186916023","repostType":4,"isVote":1,"tweetType":1,"viewCount":3310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842783902,"gmtCreate":1636244599834,"gmtModify":1636249290606,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Over aggressive expansion, Convid killed him&nbsp;","listText":"Over aggressive expansion, Convid killed him&nbsp;","text":"Over aggressive expansion, Convid killed him","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842783902","repostId":"2181744416","repostType":4,"repost":{"id":"2181744416","kind":"highlight","pubTimestamp":1636161660,"share":"https://www.laohunote.com/m/news/2181744416?lang=zh_CN&edition=full","pubTime":"2021-11-06 09:21","market":"hk","language":"en","title":"Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅店品牌海底捞将在中国关闭300家餐厅</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2181744416","media":"钛媒体","summary":"BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has ann","content":"<p>BEIJING, November 5 (TMTPOST) — <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.</p><p><blockquote>钛媒体北京11月5日电——<a href=\"https://laohu8.com/S/BPOPN\">流行的</a>中国火锅店品牌海底捞 (06862.HK) 周五宣布，将在 2021 年 12 月 31 日之前关闭中国约 300 家未能达到收入预期或客流量较低的餐厅。根据海底捞的声明，部分餐厅将暂时停业，两年内调整后重新开业。海底捞承诺不会裁员，并将重新安排在受影响餐厅工作的员工。</blockquote></p><p> Haidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.</p><p><blockquote>海底捞是中国广受欢迎的火锅店品牌，尤其受到年轻消费者的欢迎。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35715cef35710a06dc52a2418de4d934\" tg-width=\"1400\" tg-height=\"849\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Haidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.</p><p><blockquote>海底捞的业务调整计划名为《啄木鸟》，将由公司执行董事兼副首席执行官杨丽娟执导。除了密切关注海内外经营业绩不佳的海底捞餐厅外，该计划还包括重建部分关键部门、恢复区域管理体系等措施。此外，还将为各部门制定科学的关键绩效指标，同时进一步加强品牌文化的推广。业务扩张计划将因此受到限制。海底捞方面表示，如果餐桌周转率保持在每天四次以下，公司原则上不会考虑扩张。</blockquote></p><p> Haidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.</p><p><blockquote>海底捞在2020年开始大规模的业务扩张。该公司 2020 年财报显示，海底捞餐厅数量增加了 530 家，达到 1298 家。2020年，海底捞新开了544家餐厅，同时关闭了14家餐厅。然而，海底捞的翻桌率从 2019 年的每天 4.8 次下降到每天 3.5 次。</blockquote></p><p> “I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”</p><p><blockquote>“我错了。海底捞创始人张勇说：”我去年就做出了扩张的决定，结果证明这个决定是基于对市场的盲目信任。“我是在今年一月才意识到这一点的。但直到三月份，我才采取行动。”</blockquote></p><p> Haidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>海底捞的股价在今年春节后的快速增长后出现大幅跳水。海底捞股价今日上涨5.46%，收于每股21.05港元，公司估值达到1150亿港元。相比之下，海底捞的股价在 2 月份触及每股 85.75 港元，创下该公司历史新高。海底捞的估值甚至超过4600亿港元<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p></p>","source":"taimeiti","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Popular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅店品牌海底捞将在中国关闭300家餐厅</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPopular Hot Pot Restaurant Brand Haidilao to Shut Down 300 Restaurants in China<blockquote>受欢迎的火锅店品牌海底捞将在中国关闭300家餐厅</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">钛媒体</strong><span class=\"h-time small\">2021-11-06 09:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>BEIJING, November 5 (TMTPOST) — <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.</p><p><blockquote>钛媒体北京11月5日电——<a href=\"https://laohu8.com/S/BPOPN\">流行的</a>中国火锅店品牌海底捞 (06862.HK) 周五宣布，将在 2021 年 12 月 31 日之前关闭中国约 300 家未能达到收入预期或客流量较低的餐厅。根据海底捞的声明，部分餐厅将暂时停业，两年内调整后重新开业。海底捞承诺不会裁员，并将重新安排在受影响餐厅工作的员工。</blockquote></p><p> Haidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.</p><p><blockquote>海底捞是中国广受欢迎的火锅店品牌，尤其受到年轻消费者的欢迎。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/35715cef35710a06dc52a2418de4d934\" tg-width=\"1400\" tg-height=\"849\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Haidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.</p><p><blockquote>海底捞的业务调整计划名为《啄木鸟》，将由公司执行董事兼副首席执行官杨丽娟执导。除了密切关注海内外经营业绩不佳的海底捞餐厅外，该计划还包括重建部分关键部门、恢复区域管理体系等措施。此外，还将为各部门制定科学的关键绩效指标，同时进一步加强品牌文化的推广。业务扩张计划将因此受到限制。海底捞方面表示，如果餐桌周转率保持在每天四次以下，公司原则上不会考虑扩张。</blockquote></p><p> Haidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.</p><p><blockquote>海底捞在2020年开始大规模的业务扩张。该公司 2020 年财报显示，海底捞餐厅数量增加了 530 家，达到 1298 家。2020年，海底捞新开了544家餐厅，同时关闭了14家餐厅。然而，海底捞的翻桌率从 2019 年的每天 4.8 次下降到每天 3.5 次。</blockquote></p><p> “I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”</p><p><blockquote>“我错了。海底捞创始人张勇说：”我去年就做出了扩张的决定，结果证明这个决定是基于对市场的盲目信任。“我是在今年一月才意识到这一点的。但直到三月份，我才采取行动。”</blockquote></p><p> Haidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at <a href=\"https://laohu8.com/S/AONE.U\">one</a> point.</p><p><blockquote>海底捞的股价在今年春节后的快速增长后出现大幅跳水。海底捞股价今日上涨5.46%，收于每股21.05港元，公司估值达到1150亿港元。相比之下，海底捞的股价在 2 月份触及每股 85.75 港元，创下该公司历史新高。海底捞的估值甚至超过4600亿港元<a href=\"https://laohu8.com/S/AONE.U\">一</a>点。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.tmtpost.com/5842325.html?rss=qcloud\">钛媒体</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"06862":"海底捞"},"source_url":"https://www.tmtpost.com/5842325.html?rss=qcloud","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181744416","content_text":"BEIJING, November 5 (TMTPOST) — Popular Chinese hot pot restaurant brand Haidilao (06862.HK) has announced on Friday that it will close down around 300 restaurants in China that fail to meet revenue expectations or have low customer traffic by December 31st 2021. According to Haidilao’s statement, some of the restaurants will suspend operation temporarily and will reopen after adjustment within two years. Haidilao has promised that it will not lay off staff and will rearrange employees working in the affected restaurants.\nHaidilao is a popular go-to hot pot restaurant brand in China, especially popular among young consumers.\n\nHaidilao’s business adjustment plan, titled “the Woodpecker”, will be directed by the company’s executive director and vice CEO Yang Lijuan. Besides paying close attention to Haidilao restaurants with poor business performance both at home and overseas, the plan also includes measures such as rebuilding some key departments and restoring the regional management systems. In addition, scientific key performance indicators will be set up for all departments while the promotion of the brand’s culture will be further strengthened. Business expansion plans will be limited accordingly. According to Haidilao, the company will not in principle consider expanding if the table turnover rate remains lower than four times a day.\nHaidilao started a massive business expansion in 2020. The company’s 2020 fiscal report shows the number of Haidilao restaurants grew by 530 to 1,298. Haidilao opened 544 new restaurants while closing 14 restaurants in 2020. However, Haidilao’s table turnover rate decreased from 2019’s 4.8 times per day to 3.5 times per day.\n“I was wrong. I made the decision to expand last year, a decision turned out to be based on blind faith in the market,” Zhang Yong, Haidilao’s founder said. “I only realized this back in January this year. But it wasn’t until March that I took action about it.”\nHaidilao’s share price experienced a sharp dive after rapid growth after the Spring Festival earlier this year. Haidilao’s share price grew by 5.46% and closed at HK$21.05 per share today, setting the company’s valuation at HK$115 billion. In comparison, Haidilao’s share price hit HK$85.75 per share in February, a record high for the company. Haidilao’s valuation even surpassed HK$460 billion at one point.","news_type":1,"symbols_score_info":{"06862":0.9}},"isVote":1,"tweetType":1,"viewCount":2921,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827789810,"gmtCreate":1634523506698,"gmtModify":1634523506960,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Buy. No regrets&nbsp;","listText":"Buy. No regrets&nbsp;","text":"Buy. No regrets","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827789810","repostId":"1195761146","repostType":4,"isVote":1,"tweetType":1,"viewCount":3603,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827350558,"gmtCreate":1634425900287,"gmtModify":1634425900490,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"GOOD PICK&nbsp;","listText":"GOOD PICK&nbsp;","text":"GOOD PICK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827350558","repostId":"2175112192","repostType":4,"isVote":1,"tweetType":1,"viewCount":4864,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":824922247,"gmtCreate":1634271546601,"gmtModify":1634274410181,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Too high already, time for it to cool down&nbsp;","listText":"Too high already, time for it to cool down&nbsp;","text":"Too high already, time for it to cool down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/824922247","repostId":"2175197255","repostType":4,"isVote":1,"tweetType":1,"viewCount":3692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822372590,"gmtCreate":1634096770755,"gmtModify":1634096771021,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822372590","repostId":"1167212018","repostType":4,"repost":{"id":"1167212018","kind":"news","pubTimestamp":1634092916,"share":"https://www.laohunote.com/m/news/1167212018?lang=zh_CN&edition=full","pubTime":"2021-10-13 10:41","market":"us","language":"en","title":"BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG 股票：如今炙手可热的 Vinco Ventures 发生了什么？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1167212018","media":"InvestorPlace","summary":"One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventu","content":"<p><div> One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past ...</p><p><blockquote><div>Vinco Ventures（纳斯达克股票代码：BBIG）是最近引起大量散户投资者兴趣的热门股票之一。事实上，今天 BBIG 股票上涨 17% 是过去多次反弹中的一次...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG 股票：如今炙手可热的 Vinco Ventures 发生了什么？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBIG Stock: What Is Going on With Red-Hot Vinco Ventures Today?<blockquote>BBIG 股票：如今炙手可热的 Vinco Ventures 发生了什么？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-10-13 10:41</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past ...</p><p><blockquote><div>Vinco Ventures（纳斯达克股票代码：BBIG）是最近引起大量散户投资者兴趣的热门股票之一。事实上，今天 BBIG 股票上涨 17% 是过去多次反弹中的一次...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BBIG":"Vinco Ventures, Inc."},"source_url":"https://investorplace.com/2021/10/bbig-stock-what-is-going-on-with-red-hot-vinco-ventures-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167212018","content_text":"One of the red-hot stocks that’s generating a lot of retail investor interest of late is Vinco Ventures(NASDAQ:BBIG). Indeed, today’s 17% rise in BBIG stock is among a number of rallies over the past five trading days. Over this timeframe, BBIG stock has provided investors with gains of more than 20%. That is, for those with the guts to invest in this high-volatility name.\nPutting BBIG stock in perspective, this is a company that started the year around $1.35 per share. Since then, shares soared to nearly $12.50 per share last month before settling down to below $5 per share last week. What was a near 10-bagger has turned into a five-bagger. For those holding onto this stock long term, perhaps this volatility is nothing to be concerned with.\nOne of the reasons behind the rapid ebb and flow of BBIG stock has been this company’s relatively high short interest. Indeed, any highly shorted stock is one that’s likely to give retail investors goosebumps. We’ve all seen the rallies in other short squeeze stocks this year.\nHowever, there’s another catalyst investors appear to be jumping on today. Let’s dive into what’s propelling Vinco Ventures higher right now.\nBBIG Stock Surges Ahead of Key Crypto Catalyst\nToday, investors appear to be pricing in enthusiasm around a key crypto update set to be unveiled this Friday. Vinco Ventures recently provided investors with a proxy statement for a spinoff. Titled Cryptyde, this spinoff will aim to allow the company to leverage its blockchain technologies further. By doing so, the company will “disrupt consumer facing industries.”\nSounds good to me.\nInvestors appear to be growing increasingly bullish on crypto-related stocks. Crypto prices have continued to surge in recent weeks. Accordingly, companies such as Vinco Ventures that are not only short-squeeze plays but also ones with crypto exposure, represent perhaps the holy grail for speculators right now.\nHow this spinoff ultimately pans out remains to be seen. However, expectations are that BBIG stock could remain a highly volatile one for some time. Accordingly, this is a stock on my watchlist right now.","news_type":1,"symbols_score_info":{"BBIG":0.9}},"isVote":1,"tweetType":1,"viewCount":1416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829159740,"gmtCreate":1633482174945,"gmtModify":1633482175191,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Still a falling knife&nbsp;","listText":"Still a falling knife&nbsp;","text":"Still a falling knife","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/829159740","repostId":"2173911317","repostType":4,"isVote":1,"tweetType":1,"viewCount":1344,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829164011,"gmtCreate":1633481487949,"gmtModify":1633481488214,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Dead cat rebound&nbsp;","listText":"Dead cat rebound&nbsp;","text":"Dead cat rebound","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829164011","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867564866,"gmtCreate":1633302618177,"gmtModify":1633302618389,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","listText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","text":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867564866","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","kind":"news","pubTimestamp":1633152909,"share":"https://www.laohunote.com/m/news/1134305481?lang=zh_CN&edition=full","pubTime":"2021-10-02 13:35","market":"hk","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs 今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC 必须从这里开始翻倍才能重返 6 月份的高点。查看即将到来的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart 正在彻底改变消费贷款中确定信用度的方式，并且一路嘲笑银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，这是动荡的一年，但自然有些投资比其他投资表现更好。2021 年，超过 300 只股票的股价上涨了一倍多。如果许多获胜的投资能够在今年的最后三个月保持这些收益，他们将是幸运的，但那些有可能再次翻倍的名字呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>洞洞鞋</b>（纳斯达克股票代码：CROX）<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克股票代码：UPST）2021 年前 9 个月的价值增长了一倍多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1. 洞洞鞋</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那些有洞的明亮橡胶鞋吗？他们又回来了。自疫情爆发以来，Crocs 的销量一直在蓬勃发展，2021 年前 9 个月，该股也随之上涨了 129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>在 COVID-19 危机之前，舒适的树脂鞋已经卷土重来，2019 年实现了两位数的收入增长，然后在 2020 年再次实现这一壮举。2021年，动力才是真正让Crocs更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在 2 月份预计全年营收增长 20% 至 25%。接下来的一个季度，指引上调至 40% 至 50% 之间。今年夏天，这种情况再次发生，Crocs 现在的目标是 2021 年全年收入增长 60% 至 65%。您认为如果在本月晚些时候公布第三季度业绩时这些目标被推得更高，会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管该股自 2019 年初以来已上涨近六倍，但考虑到其加速增长，Crocs 的定价还是合理的。该公司的交易价格是今年市盈率的 21 倍，而明年目标仅为 17 倍。显然还有增加这些倍数的空间，华尔街终于对 Crocs 作为一项投资感到满意，就像其客户对 Crocs 的看法一样。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商出现在这个名单上，但情节转折是电影如此出色的原因。AMC院线确实已经升值——无论是股价还是流通股的五倍爆炸式增长——到了其估值相对于同行来说已经失控的地步。如果你想对电影院行业的复苏进行纯粹的投资，你会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为 ameme 股票和文化现象，很难反驳 AMC 在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢占所做的事情。今年没有一家公司的市值像 AMC 那样膨胀，但这也是一只进入第四季度的股票，其股价仅为 6 月份峰值时的一半多一点。简而言之，它必须从这里翻倍才能重新创下历史高点——但对于 2021 年动量股票的海报儿童来说，这不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在那里。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但当随后的周末表现糟糕时，最初的兴奋就消失了。然而，这都是关于管道的。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月份的上映推迟到10月份及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。第四季度对该行业来说应该比反对者想象的要强劲得多，如果 AMC 股价回到 6 月初的水平（这次基本上是盈利的），它将不得不从这里翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3. 新贵</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆时机成熟的行业被颠覆，这就是 Upstart 对贷款行业所做的事情。Upstart 使用人工智能和机器学习来更好地评级，为那些通常无法获得消费贷款批准的人评估风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎急剧放缓，过去三年增长速度分别放缓了 89%、52% 和 27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长 90%，但在最新报告中却猛增 1,018%。不，那不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。2021 年前三个季度，该股上涨了七袋，但这架颠覆性喷气式飞机的跑道还很长。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The motley fool</strong><span class=\"h-time small\">2021-10-02 13:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs 今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC 必须从这里开始翻倍才能重返 6 月份的高点。查看即将到来的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart 正在彻底改变消费贷款中确定信用度的方式，并且一路嘲笑银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，这是动荡的一年，但自然有些投资比其他投资表现更好。2021 年，超过 300 只股票的股价上涨了一倍多。如果许多获胜的投资能够在今年的最后三个月保持这些收益，他们将是幸运的，但那些有可能再次翻倍的名字呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>洞洞鞋</b>（纳斯达克股票代码：CROX）<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克股票代码：UPST）2021 年前 9 个月的价值增长了一倍多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1. 洞洞鞋</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那些有洞的明亮橡胶鞋吗？他们又回来了。自疫情爆发以来，Crocs 的销量一直在蓬勃发展，2021 年前 9 个月，该股也随之上涨了 129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>在 COVID-19 危机之前，舒适的树脂鞋已经卷土重来，2019 年实现了两位数的收入增长，然后在 2020 年再次实现这一壮举。2021年，动力才是真正让Crocs更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在 2 月份预计全年营收增长 20% 至 25%。接下来的一个季度，指引上调至 40% 至 50% 之间。今年夏天，这种情况再次发生，Crocs 现在的目标是 2021 年全年收入增长 60% 至 65%。您认为如果在本月晚些时候公布第三季度业绩时这些目标被推得更高，会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管该股自 2019 年初以来已上涨近六倍，但考虑到其加速增长，Crocs 的定价还是合理的。该公司的交易价格是今年市盈率的 21 倍，而明年目标仅为 17 倍。显然还有增加这些倍数的空间，华尔街终于对 Crocs 作为一项投资感到满意，就像其客户对 Crocs 的看法一样。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商出现在这个名单上，但情节转折是电影如此出色的原因。AMC院线确实已经升值——无论是股价还是流通股的五倍爆炸式增长——到了其估值相对于同行来说已经失控的地步。如果你想对电影院行业的复苏进行纯粹的投资，你会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为 ameme 股票和文化现象，很难反驳 AMC 在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢占所做的事情。今年没有一家公司的市值像 AMC 那样膨胀，但这也是一只进入第四季度的股票，其股价仅为 6 月份峰值时的一半多一点。简而言之，它必须从这里翻倍才能重新创下历史高点——但对于 2021 年动量股票的海报儿童来说，这不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在那里。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但当随后的周末表现糟糕时，最初的兴奋就消失了。然而，这都是关于管道的。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月份的上映推迟到10月份及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。第四季度对该行业来说应该比反对者想象的要强劲得多，如果 AMC 股价回到 6 月初的水平（这次基本上是盈利的），它将不得不从这里翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3. 新贵</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆时机成熟的行业被颠覆，这就是 Upstart 对贷款行业所做的事情。Upstart 使用人工智能和机器学习来更好地评级，为那些通常无法获得消费贷款批准的人评估风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎急剧放缓，过去三年增长速度分别放缓了 89%、52% 和 27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长 90%，但在最新报告中却猛增 1,018%。不，那不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。2021 年前三个季度，该股上涨了七袋，但这架颠覆性喷气式飞机的跑道还很长。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">The motley fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","UPST":"Upstart Holdings, Inc.","CROX":"卡骆驰"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1,"symbols_score_info":{"AMC":0.9,"CROX":0.9,"UPST":0.9}},"isVote":1,"tweetType":1,"viewCount":1483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867566905,"gmtCreate":1633302436726,"gmtModify":1633302436922,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"V good recommendations. I will include visa also&nbsp;","listText":"V good recommendations. I will include visa also&nbsp;","text":"V good recommendations. I will include visa also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867566905","repostId":"2172614079","repostType":4,"isVote":1,"tweetType":1,"viewCount":1308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":864460267,"gmtCreate":1633139179949,"gmtModify":1633139635194,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","listText":"Will report at the hell. Not worth trading&nbsp;[开心]&nbsp;","text":"Will report at the hell. Not worth trading [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/864460267","repostId":"2172968387","repostType":4,"isVote":1,"tweetType":1,"viewCount":1427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883295372,"gmtCreate":1631241789396,"gmtModify":1631883559586,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","listText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","text":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883295372","repostId":"1117851011","repostType":4,"isVote":1,"tweetType":1,"viewCount":1090,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889432961,"gmtCreate":1631167227953,"gmtModify":1631884166336,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a>Aviod, more downside to come.&nbsp;","text":"$GameStop(GME)$Aviod, more downside to come.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889432961","isVote":1,"tweetType":1,"viewCount":780,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889183816,"gmtCreate":1631114512235,"gmtModify":1631889326757,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","listText":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.&nbsp;","text":"She's playing with fire. Hopeful to win big. A dangerous speculators. Not worth following.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889183816","repostId":"1180788041","repostType":4,"repost":{"id":"1180788041","kind":"news","pubTimestamp":1631062558,"share":"https://www.laohunote.com/m/news/1180788041?lang=zh_CN&edition=full","pubTime":"2021-09-08 08:55","market":"us","language":"en","title":"Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最热门的投资者正在大力押注少数股票。批评家说她在玩火</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1180788041","media":"CNN Business","summary":"New York  - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.It's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.Last year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation exchange-traded fund. It surged nearly 150% in 2020","content":"<p><div> New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy ...</p><p><blockquote><div>纽约（CNN Business）-当许多投资者满足于随波逐流，购买苹果、亚马逊和微软等顶级科技公司时，凯西·伍德正在寻找buzzy的下一个大创新者……</div></blockquote></p><p>  <a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">网页连接</a></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最热门的投资者正在大力押注少数股票。批评家说她在玩火</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street's hottest investor is betting big on a handful of stocks. Critics say she's playing with fire<blockquote>华尔街最热门的投资者正在大力押注少数股票。批评家说她在玩火</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">CNN Business</strong><span class=\"h-time small\">2021-09-08 08:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy ...</p><p><blockquote><div>纽约（CNN Business）-当许多投资者满足于随波逐流，购买苹果、亚马逊和微软等顶级科技公司时，凯西·伍德正在寻找buzzy的下一个大创新者……</div></blockquote></p><p>  <a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html\">CNN Business</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","ARKW":"ARK Next Generation Internet ETF","ARKG":"ARK Genomic Revolution ETF","TSLA":"特斯拉","ARKF":"ARK Fintech Innovation ETF"},"source_url":"https://edition.cnn.com/2021/09/07/investing/cathie-wood-risk-takers/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180788041","content_text":"New York (CNN Business) - At a time when many investors are content to follow the crowd and buy top techs like Apple, Amazon and Microsoft, Cathie Wood is looking for the next big innovators in buzzy fields like robotics, fintech and space exploration.\nIt's a high-flying, high-risk, high-reward tier of investing. And it's put Wood's fans on a white-knuckle ride in 2021.\nLast year, Wood's strategy paid huge dividends for investors in her flagship Ark Innovation(ARKK) exchange-traded fund. It surged nearly 150% in 2020 and helped turn her into a Wall Street superstar — sort of the Warren Buffett of momentum investing.\nCathie Wood, CEO of Ark Investment Management, has become the face of the growth stock movement on Wall Street.\nBut this year hasn't been nearly as kind to Wood as the last. The Innovation ETF was down 2.5% through late August, despite a red-hot market for tech with the Nasdaq up more than 18% so far in 2021.\nWood wasn't available to comment for this story, but she doubled down in an interview with CNBC in August. She's not worried that the Ark strategy of looking for new tech leaders will end badly, and she maintains that this current rally will not be a repeat of the epic 2000 dot-com implosion.\n\"I don't think we're in a bubble, which is what I think many bears think we are,\" Wood told CNBC. \"We have nothing like that right now. In fact, you see a lot of IPOs or SPACs coming out and falling to Earth. We couldn't be further away from a bubble.\"\nHow Wood developed her strategy\nWood speaks from experience. She's no millennial or Gen Z investor for whom the 2000 tech implosion is merely a war story told by older traders. The 65-year-old Wood lived through the last major tech crash, as well as the infamous Black Monday of 1987.\nShe worked for Prudential-owned money manager Jennison Associates for 18 years in the 1980s and 1990s and then spent a dozen years at AllianceBernstein before leaving in 2013.\nBut then, AllianceBernstein passed on her idea to launch a suite of actively managed exchange-traded funds. So she struck out on her own and started Ark in 2014.\n\"I have been watching disruptive innovation for my entire career — why don't I help my own sector along?\" she told Forbes in a 2014 interview.\nThat focus on disruption means Wood ties her ETF's fortunes to visionary but mercurial leaders.\nIn the most prominent example, Wood remains an unabashed fan of Tesla(TSLA) and CEO Elon Musk. The EV maker is the top stock, by far, in Ark's Innovation ETF, accounting for more than 10% of the fund's holdings. It's also the biggest position in Ark's Autonomous Technology & Robotics(ARKQ) and Next Generation Internet(ARKW) ETFs.\nWood is a vocal fan of Tesla, which is a top holding in several of Ark's funds.\nWood is also OK with companies like Tesla issuing more stock to raise money to fund futuristic projects like autonomous vehicles. Some investors are wary of that strategy because the new shares lower the value of existing investors' holdings, but she thinks that's a short-sighted argument, particularly from Tesla bears.\n\"We're not afraid of dilution ... if we think they're doing it for the right reason,\" she told CNBC. \"We wanted them to scale as quickly as possible because we think if we're right on autonomous ...Tesla could get the lion's share of that market, certainly in the United States.\"\nArk's big investment in Tesla is a bet on Musk continuing to innovate beyond the business of electric cars, Wood explained in an interview with Bloomberg Radio in August. She raved about Tesla's plans to build a humanoid robot, for example.\n\"Every passing day, especially the more we learn about their AI expertise and how they're really driving the space ... we believe they have the pole position,\" she said, noting that Ark analysts were \"blown away\" by Musk's presentation.\nGrowth at all costs\nWood recognizes her growth-at-all-costs way of investing is not for everyone.\nTesla has lagged the broader market this year. Shares of Teladoc(TDOC), a telehealth company that is the second-largest holding in the Ark Innovation ETF and was a big winner at the start of the pandemic, are down more than 25% in 2021.\n\"We've seen higher-valuation stocks hit hard this year. But the growth for these innovative companies will still be treated well over time,\" Wood said during a webcast hosted by Cboe Global Markets in March.\nWood added that she thinks investors also should put a small percentage of their money in bitcoin, another risky bet. And she stressed that investors have to overlook the inevitable short-term bumps that come with any asset. It's essential to maintain longer-term convictions and invest for future growth, Wood believes.\n\"A lot of companies catering to short-term investors who wanted profits now [have] invested more in stock buybacks and dividends over innovation,\" she said. \"That puts them in harm's way.\"\nA colleague describes Wood's go-big-or-go-home approach as a model for the new way of investing. Too many fund managers are afraid to look far into the future when judging a company's merits, instead focusing myopically on the prior and next quarterly earnings reports.\n\"Cathie has been focusing on Tesla for a long time. She looks at it not just as an automobile manufacturer. You can't compare it to traditional car companies,\" Ark Invest's Ren Leggi, who works closely with Wood on investment decisions as the company's client portfolio manager, told CNN Business in March.\nWood's critics\nBut a growing chorus of skeptics think Wood's funds could eventually collapse. Michael Burry, one of the super-bearish investors made famous in \"The Big Short,\" recently established a short position on the Ark Innovation ETF — essentially betting that it will fall sharply.\nSome tech stock veterans also wonder if Wood is just an investing flavor of the month, comparing her to once-popular portfolio managers like Kevin Landis of Firsthand Funds, Alberto Vilar of Amerindo and Garrett Van Wagoner, who ran a popular emerging-growth fund in the late 1990s.\nMany of those tech funds imploded following the 2000 bubble. TheWall Street Journalwrote a catch-up piece about Van Wagoner and other late 1990s tech gurus in 2010 with the headline \"From Fame, Fortune to Flamed-Out Stars. Post-Bust Fates of Tech-Fund Mavens.\"\nIs Wood destined for similar ignominy?\nRivals take issue with Wood making such big bets on only a handful of stocks. The Ark Innovation ETF, for example, has nearly half its assets concentrated in its top 10 holdings. Beyond Tesla, that fund also owns sizable stakes in Roku(ROKU),Coinbase,Zoom(ZM) and Square(SQ).\nRoku is another example of a high-risk/high-reward stock that Wood loves.\n\"Our investment approach is similar to Ark in that we are focusing on tech. But we're different in that we avoid concentration,\"Jeremie Capron, head of research at ROBO Global, told CNN Business in March.\nThe top 10 holdings in theROBO Global Robotics and Automation Index(ROBO)ETF account for less than 20% of the fund's total assets, and the fund owns about 80 stocks. Ark funds typically own shares in only about 30 to 50 companies.\nFor the time being, Wood is having the last laugh.\nYes, her fund's returns may be volatile year-to-year — the Ark Innovation ETF fell nearly 25% in 2018 before rebounding 30% in 2019 — but it has tended to smooth out. The five-year average annualized return for the Ark Innovation ETF through mid-2021 was 48.6%, compared to 17.7% for the S&P 500.\nAs long as that long-term trend continues, Ark acolytes may forgive a down year every now and then as Wood continues to swing for the fences.","news_type":1,"symbols_score_info":{"TSLA":0.9,"ARKF":0.9,"ARKG":0.9,"ARKK":0.9,"ARKW":0.9}},"isVote":1,"tweetType":1,"viewCount":838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814279210,"gmtCreate":1630833660230,"gmtModify":1631884234829,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","listText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","text":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814279210","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":883295372,"gmtCreate":1631241789396,"gmtModify":1631883559586,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","listText":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped&nbsp;","text":"See, con women, say Tesla worth $3000/share, but dump it after her announcement not long ago. Her followers all have to safe keep those she dumped","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/883295372","repostId":"1117851011","repostType":4,"isVote":1,"tweetType":1,"viewCount":1090,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814279210,"gmtCreate":1630833660230,"gmtModify":1631884234829,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","listText":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt&nbsp;","text":"This lady fickle minded, be more careful if u follow her. Anyway, she's right this time to buy into China mkt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/814279210","repostId":"2164808914","repostType":4,"isVote":1,"tweetType":1,"viewCount":834,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":824922247,"gmtCreate":1634271546601,"gmtModify":1634274410181,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Too high already, time for it to cool down&nbsp;","listText":"Too high already, time for it to cool down&nbsp;","text":"Too high already, time for it to cool down","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/824922247","repostId":"2175197255","repostType":4,"isVote":1,"tweetType":1,"viewCount":3692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877922815,"gmtCreate":1637881319600,"gmtModify":1637881319742,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","listText":"Will it ? Well market is insane, anything can happen&nbsp;[开心]&nbsp;[开心]&nbsp;","text":"Will it ? Well market is insane, anything can happen [开心] [开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/877922815","repostId":"2186916023","repostType":4,"isVote":1,"tweetType":1,"viewCount":3310,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867564866,"gmtCreate":1633302618177,"gmtModify":1633302618389,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","listText":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful&nbsp;","text":"Still need to be careful with amc, virus situation still bad. It could mutate again and become more resilient and powerful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/867564866","repostId":"1134305481","repostType":4,"repost":{"id":"1134305481","kind":"news","pubTimestamp":1633152909,"share":"https://www.laohunote.com/m/news/1134305481?lang=zh_CN&edition=full","pubTime":"2021-10-02 13:35","market":"hk","language":"en","title":"3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134305481","media":"The motley fool","summary":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this mo","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs 今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC 必须从这里开始翻倍才能重返 6 月份的高点。查看即将到来的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart 正在彻底改变消费贷款中确定信用度的方式，并且一路嘲笑银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，这是动荡的一年，但自然有些投资比其他投资表现更好。2021 年，超过 300 只股票的股价上涨了一倍多。如果许多获胜的投资能够在今年的最后三个月保持这些收益，他们将是幸运的，但那些有可能再次翻倍的名字呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>洞洞鞋</b>（纳斯达克股票代码：CROX）<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克股票代码：UPST）2021 年前 9 个月的价值增长了一倍多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1. 洞洞鞋</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那些有洞的明亮橡胶鞋吗？他们又回来了。自疫情爆发以来，Crocs 的销量一直在蓬勃发展，2021 年前 9 个月，该股也随之上涨了 129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>在 COVID-19 危机之前，舒适的树脂鞋已经卷土重来，2019 年实现了两位数的收入增长，然后在 2020 年再次实现这一壮举。2021年，动力才是真正让Crocs更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在 2 月份预计全年营收增长 20% 至 25%。接下来的一个季度，指引上调至 40% 至 50% 之间。今年夏天，这种情况再次发生，Crocs 现在的目标是 2021 年全年收入增长 60% 至 65%。您认为如果在本月晚些时候公布第三季度业绩时这些目标被推得更高，会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管该股自 2019 年初以来已上涨近六倍，但考虑到其加速增长，Crocs 的定价还是合理的。该公司的交易价格是今年市盈率的 21 倍，而明年目标仅为 17 倍。显然还有增加这些倍数的空间，华尔街终于对 Crocs 作为一项投资感到满意，就像其客户对 Crocs 的看法一样。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商出现在这个名单上，但情节转折是电影如此出色的原因。AMC院线确实已经升值——无论是股价还是流通股的五倍爆炸式增长——到了其估值相对于同行来说已经失控的地步。如果你想对电影院行业的复苏进行纯粹的投资，你会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为 ameme 股票和文化现象，很难反驳 AMC 在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢占所做的事情。今年没有一家公司的市值像 AMC 那样膨胀，但这也是一只进入第四季度的股票，其股价仅为 6 月份峰值时的一半多一点。简而言之，它必须从这里翻倍才能重新创下历史高点——但对于 2021 年动量股票的海报儿童来说，这不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在那里。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但当随后的周末表现糟糕时，最初的兴奋就消失了。然而，这都是关于管道的。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月份的上映推迟到10月份及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。第四季度对该行业来说应该比反对者想象的要强劲得多，如果 AMC 股价回到 6 月初的水平（这次基本上是盈利的），它将不得不从这里翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3. 新贵</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆时机成熟的行业被颠覆，这就是 Upstart 对贷款行业所做的事情。Upstart 使用人工智能和机器学习来更好地评级，为那些通常无法获得消费贷款批准的人评估风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎急剧放缓，过去三年增长速度分别放缓了 89%、52% 和 27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长 90%，但在最新报告中却猛增 1,018%。不，那不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。2021 年前三个季度，该股上涨了七袋，但这架颠覆性喷气式飞机的跑道还很长。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Can Double Again in the Fourth Quarter<blockquote>3只股票第四季度可能再次翻倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The motley fool</strong><span class=\"h-time small\">2021-10-02 13:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul>  <li>Crocs has jacked up its guidance every quarter this year. It reports again later this month.</li>  <li>AMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.</li>  <li>Upstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.</li> </ul> </p><p><blockquote><ul><li>Crocs 今年每个季度都上调了指引。它将于本月晚些时候再次报道。</li><li>AMC 必须从这里开始翻倍才能重返 6 月份的高点。查看即将到来的影院上映名单，了解为什么电影院会变得更好。</li><li>Upstart 正在彻底改变消费贷款中确定信用度的方式，并且一路嘲笑银行。</li></ul></blockquote></p><p> It's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?</p><p><blockquote>对于股市来说，这是动荡的一年，但自然有些投资比其他投资表现更好。2021 年，超过 300 只股票的股价上涨了一倍多。如果许多获胜的投资能够在今年的最后三个月保持这些收益，他们将是幸运的，但那些有可能再次翻倍的名字呢？</blockquote></p><p> <b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>AMC Entertainment</b>(NYSE:AMC), and<b>Upstart</b>&nbsp;(NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.</p><p><blockquote><b>洞洞鞋</b>（纳斯达克股票代码：CROX）<b>AMC院线</b>（纽约证券交易所代码：AMC），以及<b>暴发户</b>（纳斯达克股票代码：UPST）2021 年前 9 个月的价值增长了一倍多。让我们看看为什么他们有能力在第四季度重复这一壮举。</blockquote></p><p> 1. Crocs</p><p><blockquote>1. 洞洞鞋</blockquote></p><p> Remember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.</p><p><blockquote>还记得那些有洞的明亮橡胶鞋吗？他们又回来了。自疫情爆发以来，Crocs 的销量一直在蓬勃发展，2021 年前 9 个月，该股也随之上涨了 129%。</blockquote></p><p> The comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.</p><p><blockquote>在 COVID-19 危机之前，舒适的树脂鞋已经卷土重来，2019 年实现了两位数的收入增长，然后在 2020 年再次实现这一壮举。2021年，动力才是真正让Crocs更上一层楼的原因。</blockquote></p><p> The year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?</p><p><blockquote>今年年初，这家鞋类制造商在 2 月份预计全年营收增长 20% 至 25%。接下来的一个季度，指引上调至 40% 至 50% 之间。今年夏天，这种情况再次发生，Crocs 现在的目标是 2021 年全年收入增长 60% 至 65%。您认为如果在本月晚些时候公布第三季度业绩时这些目标被推得更高，会发生什么？</blockquote></p><p> Despite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.</p><p><blockquote>尽管该股自 2019 年初以来已上涨近六倍，但考虑到其加速增长，Crocs 的定价还是合理的。该公司的交易价格是今年市盈率的 21 倍，而明年目标仅为 17 倍。显然还有增加这些倍数的空间，华尔街终于对 Crocs 作为一项投资感到满意，就像其客户对 Crocs 的看法一样。</blockquote></p><p> 2. AMC Entertainment</p><p><blockquote>2.AMC院线</blockquote></p><p> You may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.</p><p><blockquote>你可能会惊讶地发现这个国家领先的多厅影院运营商出现在这个名单上，但情节转折是电影如此出色的原因。AMC院线确实已经升值——无论是股价还是流通股的五倍爆炸式增长——到了其估值相对于同行来说已经失控的地步。如果你想对电影院行业的复苏进行纯粹的投资，你会发现价格更具吸引力的股票。</blockquote></p><p> However, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?</p><p><blockquote>然而，作为 ameme 股票和文化现象，很难反驳 AMC 在复苏过程中将其在散户投资者中的受欢迎程度转化为合法的市场份额抢占所做的事情。今年没有一家公司的市值像 AMC 那样膨胀，但这也是一只进入第四季度的股票，其股价仅为 6 月份峰值时的一半多一点。简而言之，它必须从这里翻倍才能重新创下历史高点——但对于 2021 年动量股票的海报儿童来说，这不总是可能的吗？</blockquote></p><p> Fundamentally speaking, the catalysts are also there.<i>Shang-Chi and the Legend of the Ten Rings</i>shattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.</p><p><blockquote>从根本上说，催化剂也在那里。<i>尚气与十环传说</i>劳动节周末打破了票房记录，但当随后的周末表现糟糕时，最初的兴奋就消失了。然而，这都是关于管道的。当德尔塔变异毒株导致新冠肺炎病例激增时，电影公司将9月份的上映推迟到10月份及以后。我们现在看到备受期待的电影开始回归，从下周末的新詹姆斯·邦德电影开始。第四季度对该行业来说应该比反对者想象的要强劲得多，如果 AMC 股价回到 6 月初的水平（这次基本上是盈利的），它将不得不从这里翻一番。</blockquote></p><p> 3. Upstart</p><p><blockquote>3. 新贵</blockquote></p><p> I love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.</p><p><blockquote>我喜欢颠覆时机成熟的行业被颠覆，这就是 Upstart 对贷款行业所做的事情。Upstart 使用人工智能和机器学习来更好地评级，为那些通常无法获得消费贷款批准的人评估风险状况和信用度。</blockquote></p><p> Growth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.</p><p><blockquote>增长是疯狂的。收入似乎急剧放缓，过去三年增长速度分别放缓了 89%、52% 和 27%。现在，消费者开始意识到Upstart是发薪日贷款和其他掠夺性贷款产品的更好替代品，业务正在飙升。第一季度收入增长 90%，但在最新报告中却猛增 1,018%。不，那不是错别字。</blockquote></p><p></p><p> With Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.</p><p><blockquote>随着Upstart现在扩展到汽车贷款市场，其更好的替代乏味信用评分的潜力才刚刚开始。2021 年前三个季度，该股上涨了七袋，但这架颠覆性喷气式飞机的跑道还很长。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/\">The motley fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","UPST":"Upstart Holdings, Inc.","CROX":"卡骆驰"},"source_url":"https://www.fool.com/investing/2021/10/01/3-stocks-that-can-double-again-in-the-fourth-quart/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134305481","content_text":"Key Points\n\nCrocs has jacked up its guidance every quarter this year. It reports again later this month.\nAMC would have to double from here to revisit its June highs. Check the upcoming theatrical release slate to know why movie theaters are about to get a whole lot better.\nUpstart is revolutionizing the way creditworthiness is determined in consumer loans, and it's laughing all the way to the bank.\n\n\nIt's been a volatile year for stocks, but naturally some investments have fared better than others. Over 300 stocks have more than doubled in 2021. Many of those winning investments will be lucky if they can hold those gains through the final three months of the year, but what about the names that have the potential to double again?\nCrocs (NASDAQ:CROX),AMC Entertainment(NYSE:AMC), andUpstart (NASDAQ:UPST)have more than doubled in value through the first nine months of 2021. Let's see why they have what it takes to possibly repeat the feat in the fourth quarter.\n1. Crocs\nRemember those bright rubbery shoes with holes in them? They're back in a big way. Crocs sales are booming since the pandemic began, and the stock is following suit with a 129% increase through the first nine months of 2021.\nThe comfortable resin shoes were already making a comeback before the COVID-19 crisis with double-digit revenue growth in 2019 before repeating the feat in 2020. Momentum is what's really taking Crocs to a higher level in 2021.\nThe year began with the footwear maker projecting 20%-to-25% top-line growth for the entire year back in February. Guidance was bumped higher -- to between 40% and 50% growth -- the following quarter. It happened again this summer, with Crocs now targeting a 60%-to-65% surge in revenue for all of 2021. What do you think will happen if those targets get pushed even higher when it reports third-quarter results later this month?\nDespite a stock that has popped nearly sixfold since the start of 2019, Crocs is reasonably priced given its accelerating growth. It's trading at 21 times this year's earnings and just 17 times next year's target. There's clearly room to increase those multiples, and Wall Street's finally as comfortable with Crocs as an investment as its customers are in its shoes.\n2. AMC Entertainment\nYou may be surprised to find the country's leading multiplex operator on this list, but plot twists are what make movies so good. It's certainly true that AMC Entertainment has appreciated -- in terms of both stock price and a fivefold explosion in shares outstanding -- to the point where its valuation is out of whack relative to its peers'. If you want a pure investing play on the movie theater industry's recovery, you will find more attractively priced stocks toscratchthatitch.\nHowever, as ameme stockand cultural phenomenon it's hard to argue against what AMC has done to translate its popularity among retail investors into a legitimate market share grab in the recovery process. No company has seen its market cap inflate as much as AMC has this year, but this is also a stock that enters the fourth quarter with a stock price that is a little more than half of what it was when it peaked in June. In short, it would have to double from here to revisit its all-time high -- but isn't that always possible with the poster child for 2021 momentum stocks?\nFundamentally speaking, the catalysts are also there.Shang-Chi and the Legend of the Ten Ringsshattered box office records over Labor Day weekend, but the initial excitement fizzled out when subsequent weekends were abysmal. However, it's all about the pipeline. Studios pushed out September releases into October and beyond when the delta variant resulted in a spike in COVID-19 cases. We're now seeing the highly anticipated films start to come back, starting with the new James Bond movie next weekend. The fourth quarter should be a lot stronger for the industry than the naysayers think, and if AMC stock gets back to where it was in early June -- fundamentally earned this time -- it will have to double from here.\n3. Upstart\nI love when industries ripe for disruption get upended, and that's what Upstart is doing with the lending industry. Upstart usesartificial intelligenceand machine learning to make better calls on assessing risk profiles and creditworthiness for folks who don't typically get approved for consumer loans.\nGrowth is bonkers. Revenue seemed to be decelerating sharply, with slowing growth spurts of 89%, 52%, and 27% in the last three years respectively. Now that consumers are becoming aware of Upstart as a better alternative to payday loans and other predatory lending products, business is skyrocketing. Revenue rose 90% in the first quarter, only to surge 1,018% in its latest report. And no, that's not a typo.\nWith Upstart now expanding into the auto loans market, the potential for its better alternative to stodgy credit scores is just getting started. The stock has been a seven-bagger through the first three quarters of 2021, but the runway is long for this disruptive jet.","news_type":1,"symbols_score_info":{"AMC":0.9,"CROX":0.9,"UPST":0.9}},"isVote":1,"tweetType":1,"viewCount":1483,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":867566905,"gmtCreate":1633302436726,"gmtModify":1633302436922,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"V good recommendations. I will include visa also&nbsp;","listText":"V good recommendations. I will include visa also&nbsp;","text":"V good recommendations. I will include visa also","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/867566905","repostId":"2172614079","repostType":4,"isVote":1,"tweetType":1,"viewCount":1308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699267737,"gmtCreate":1639815129172,"gmtModify":1639815129921,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Semicon industry nvr die","listText":"Semicon industry nvr die","text":"Semicon industry nvr die","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699267737","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","kind":"news","pubTimestamp":1639806035,"share":"https://www.laohunote.com/m/news/1161245886?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>韦德布什证券董事总经理丹·艾夫斯建议投资者坚持投资科技股，尽管美联储加息可能会出现潜在的估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是放弃科技的时候，”他周五对 CNBC 表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">缩放器</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技下行趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的巨额支出以及进一步向云迁移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内增加 2 万亿美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须对投资组合进行选择性，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从疫情中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA 在 2021 年的表现是迄今为止最好的，一年内上涨了一倍多。ZS 和 PANW 均上涨近 50%。AAPL 落后于规模较小的竞争对手，尽管它在 2021 年上涨了约 30%。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团中主要落后的是CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-18 13:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>韦德布什证券董事总经理丹·艾夫斯建议投资者坚持投资科技股，尽管美联储加息可能会出现潜在的估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是放弃科技的时候，”他周五对 CNBC 表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">缩放器</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技下行趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的巨额支出以及进一步向云迁移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内增加 2 万亿美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须对投资组合进行选择性，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从疫情中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA 在 2021 年的表现是迄今为止最好的，一年内上涨了一倍多。ZS 和 PANW 均上涨近 50%。AAPL 落后于规模较小的竞争对手，尽管它在 2021 年上涨了约 30%。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团中主要落后的是CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CYBR":"Cyber-Ark Software","ZS":"Zscaler Inc.","PANW":"Palo Alto Networks","NVDA":"英伟达"},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1,"symbols_score_info":{"PANW":0.9,"ZS":0.9,"NVDA":0.9,"CYBR":0.9}},"isVote":1,"tweetType":1,"viewCount":4935,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":895424082,"gmtCreate":1628767853846,"gmtModify":1631889326805,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"Not worth buying. Follow her and die faster&nbsp;","listText":"Not worth buying. Follow her and die faster&nbsp;","text":"Not worth buying. Follow her and die faster","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/895424082","repostId":"2158257251","repostType":4,"isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":827350558,"gmtCreate":1634425900287,"gmtModify":1634425900490,"author":{"id":"3574662162410712","authorId":"3574662162410712","name":"Ericdao","avatar":"https://static.tigerbbs.com/bc892cea22318ad4afece18be23b502b","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574662162410712","authorIdStr":"3574662162410712"},"themes":[],"title":"","htmlText":"GOOD PICK&nbsp;","listText":"GOOD PICK&nbsp;","text":"GOOD PICK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/827350558","repostId":"2175112192","repostType":4,"isVote":1,"tweetType":1,"viewCount":4864,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}